 
 
PEGCETACOPLAN (APL -2) 
PROTOCOL APL2-304 
A PHASE 3, MULTICENTER, RANDOMIZED, 
DOUBLE -MASKED, SHAM -CONTROLLED STUDY TO 
COMPARE THE EFFICACY AND SAFETY OF 
INTRAVITREAL PEGCETACOPLAN THERAPY WITH 
SHAM INJECTIONS IN PATIENTS WITH 
GEOGRAPHIC ATROPHY (GA) SECONDARY TO 
AGE -RELATED MACULAR DEGENERATION (AMD)  
 
US IND No. : [ADDRESS_1144170] No.:  2018-001435-52 
Phase: 3 
Version:  Amendment 5 
Date:  [ADDRESS_1144171] 202 0 
INVESTIGAT OR AGREEMENT  
Long Title :  A Phase 3, Multi-Center, Randomized, Double-
Masked, Sham-Controlled Study to Compare the 
Efficacy and Safety of Intravitreal Pegcetacoplan  
Therapy with Sham Injections in Patients with 
Geographic Atrophy (GA) Secondary to Age-
Related Macular Degeneration (AMD)  
Short  Title :  Oaks  
Protocol Number , Version,  and Date : APL2 -304 / Amendment 5 / [ADDRESS_1144172] 2020  
Study  Phase :  Phase 3  
Sponsor  Name  [CONTACT_1781] :  Apellis Pharmaceuticals, Inc  
 [ADDRESS_1144173]  Article:  Pegcetacoplan  intravitreal injection  (also known as 
APL -2) 
US IND Number:  [ADDRESS_1144174] Number:  2018-001435-52  
Indication Studied: Geographic atrophy secondary to age- related 
macular degeneration  
Investigator Agreement : I have read  the clinical  study described  herein , 
recognize its  confidentiality , and  agree to  conduct 
the described  trial in compliance with  Good Clinical 
Practice ( GCP ), the ethical  principles contained  
within  the Declaration  of Helsinki, this  protocol, 
and all applicable regulatory requirements .  
 
 Principal  Investigator :  
 [CONTACT_5627]: ____________________________________ 
  Signature : _________________________________  
 
 Date: ______/______/______ ( DD/MMM/ YYYY ) 
 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144175] 202 0 
PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Amendment 5: Summary of Changes From the Previous Version  
Amendment Date: [ADDRESS_1144176] 2020 Updates to the protocol implemented in th is amendment are provided in the table below.  
Description of change  Section(s) affected by [CONTACT_825148].  Entire document  
Updated company address  Investigator Agreement and Sponsor Information  
Changed APL -2 to International Nonproprietary Name : [CONTACT_825186], 
updated related abbreviations and protocol title  Entire document  
Added the descriptor “maximum” when referencing reading speed Synops is, Section  5.1.2, 
Section  5.1.5, Section  12.7.2, 
Section  12.7.3  
Removed the 6 -month follow -up period and updated the study length 
from 30 mon ths to 24 months and made it a 30- or 60- day follow -up 
period based on treatment group because that length of time is deemed 
sufficient to evaluate the safety of pegcetacoplan based on its half -life in 
the vitreous. Additionally, there is an option for subjects to enroll in a separate extension study ( Study  APL2 -GA-305) during which longer -
term safety and efficacy will be collected.  Synopsis , Section  8, 
Section  [IP_ADDRESS].1 , Section  11.8 
Inclusion criterion  6c was updated from “ Reliability test ratio must be 
≤20%” to “Fixation losses must be ≤20% ” on the basis of regulatory 
feedback  provided to the microperimetry device manuf acturer  Synopsis , Section  6.1.1  
Updated the text regarding the sample size to both simplify and reduce redundancies  Synopsis , Section  12.5 
Previous Section  [IP_ADDRESS] , Pharmacokinetics , moved to Section  [IP_ADDRESS] to 
follow Section  [IP_ADDRESS] , Toxicology  Section  [IP_ADDRESS], Section  [IP_ADDRESS]  
Updated the formulation information  Section  4.1.2, Section  [IP_ADDRESS]  
Revised number of injections for each treatment arm because the 
injections at Month 24 will no longer be administered Section  7.3.1 ( Table 1 ), Section  [ADDRESS_1144177] -2 investigator’s brochure  from references  Section  [ADDRESS_1144178] OF FIGURES  .......................................................................................................................11  
2. SYNOPSIS  .................................................................................................................12  
3. ABBREVIATIONS  ....................................................................................................20  
4. INTRODUCTION  ......................................................................................................23  
4.1. Background .................................................................................................................23  
4.1.1.  Age-Related Macular Degeneration  .....................................................................23  
4.1.2.  Pegcetacoplan  .......................................................................................................23  
4.1.3.  Nonclinical Data  ...................................................................................................24  
  
  
4.1.4.  Clinical Data  .........................................................................................................27  
4.1.5.  Rationale  ...............................................................................................................28  
[IP_ADDRESS].  Rationale for Pegcetacoplan for  Treatment of Geographic 
Atrophy .....................................................................................................28  
4.1.6.  Dose Selection  ......................................................................................................28  
4.2. Risk/Benefit ................................................................................................................[ADDRESS_1144179] 202 0 
6.1.2.  Exclusion Criteria  .................................................................................................33  
6.2. Women of Childbearin g Potential  ..............................................................................34  
6.3. Women of Nonchildbearing Potential ........................................................................34  
6.4. Approved Methods of Contraception .........................................................................34  
6.5. Discontinuation of Subjects ........................................................................................35  
7. TREATMENT OF SUBJECTS  ..................................................................................36  
7.1. Allocation to Treatment  ..............................................................................................36  
7.2. Masking and Minimizatio n of Bias ............................................................................36  
7.2.1.  Unmasking ............................................................................................................37  
7.3. Dosage and Administration ........................................................................................37  
7.3.1.  Dose Levels and Treatment Arms  ........................................................................37  
7.3.2.  Treatment Ad ministration  .....................................................................................37  
7.3.3.  Drug Supplies .......................................................................................................38  
[IP_ADDRESS].  Identity of Investigational Product ...........................................................38  
[IP_ADDRESS].  Storage ......................................................................................................38  
[IP_ADDRESS].  Accountability  ...........................................................................................38  
7.3.4.  Intravitreal Pegcetacoplan Administration  ...........................................................39  
7.4. Sham Injection Administration  ...................................................................................39  
7.5. Concomitant Therapi[INVESTIGATOR_014] ...............................................................................................39  
7.5.1.  Treatment of New Exudation Related to Active Choroidal 
Neovascularization in the Study Eye and/or Fellow Eye ...............................39  
7.5.2.  Prohibited Therapi[INVESTIGATOR_014] .............................................................................................40  
7.5.3.  Endophthalmitis Treatment ..................................................................................40  
8. STUDY PROCEDURES  ............................................................................................42  
8.1. Study Visit Schedule ...................................................................................................43  
8.1.1.  Screening Period —Within 28 Days Prior to Randomization/ Treatment 
(Day –28 to –1) ...............................................................................................43  
[IP_ADDRESS].  Visit 1—All Subjects  ................................................................................43  
8.1.2.  Randomization/ Initial Treatment—Day  1—Within 28 Days of 
Screening  ........................................................................................................44  
[IP_ADDRESS].  Visit 2—All Groups ..................................................................................44  
8.1.3.  Treatment Phase—24 Months ..............................................................................44  
[IP_ADDRESS].  Months 1-[ADDRESS_1144180] 202 0 
[IP_ADDRESS].  Months 13-24 ............................................................................................45  
8.1.4.  Early Termination Visit ........................................................................................46  
8.1.5.  Unscheduled Visits ...............................................................................................46  
9. ASSESSMENTS .........................................................................................................47  
9.1. Informed Consent .......................................................................................................47  
9.2. Demographic Information/ Medical/ Surgical History  ...............................................47  
9.3. Ocular History/ Ocular Procedures  .............................................................................[ADDRESS_1144181]  .................................................................................................48  
9.9. Patient -Reported Outcomes  ........................................................................................49  
9.9.1.  The National Eye Institute Visual Functioning Questionnaire 25- Item 
Version (NEI- VFQ)  ........................................................................................49  
9.9.2.  The Functional Reading Independence (FRI) Index ............................................[ADDRESS_1144182] Corrected Visual 
Acuity  ...................................................................................................................49  
9.11.  Minnesota Low-Vision Reading (MNREAD) Test or Radner Reading Charts 
(in select countries)  ...............................................................................................50  
9.12.  Home -Based Functional Digital Applications (optional, select sites)  ........................50  
9.13.  Complete Ophthalmic Exam .......................................................................................50  
9.14.  Ocular Imaging and M icroperimetry  ..........................................................................50  
9.15.  Postinjection Assessment............................................................................................51  
9.16.  Blood Volume for Study Assessments .......................................................................52  
9.17.  Samples for Clinical Repository (Optional, Select Sites)  ...........................................[ADDRESS_1144183]/Ethic Committee  .............................................................[ADDRESS_1144184] Access to Source Data/Documents  ..................................................................[ADDRESS_1144185] Keepi[INVESTIGATOR_007] ...........................................................................67  
14.5.  Protocol Amendments ................................................................................................68  
14.6.  Report Format .............................................................................................................68  
14.7.  Finance and Insurance ................................................................................................68  
14.8.  Publication Policy  .......................................................................................................68  
14.9.  ClinicalTrials .gov .......................................................................................................69  
14.10.  Termination of Study ..................................................................................................69  
15. REFERENCES  ...........................................................................................................70  
16. APPENDICES  ............................................................................................................72  
APPENDIX A: VISIT SCHEDULE —Monthly Group—Screening, Day  1 through 
Month 12 ...............................................................................................................72  
APPENDIX B: VISIT SCHEDULE —Monthly Group—Month 13 to Month 24 ..................75  
APPENDIX C: VISIT SCHEDULE —Every -Other -Month Group—Screening, Day 1 
Through Month 12 ................................................................................................78  
APPENDIX D: VISIT SCHEDULE —Every -Other -Month Group—Month 13 to 
Month 24 ...............................................................................................................81  
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25 -ITEM VERSION  ............................................................84  
APPENDIX F: FUNCTIONAL READING INDEPENDENCE INDEX (FRI)  ...................101  
APPENDIX G: MINNESOTA LOW -VISION READING TEST (MNREAD) AND 
RADNER READING CARDS ...........................................................................102  
APPENDIX H: GRADING SCALE FOR ASSESSMENT OF ANTERIOR  
CHAMBER FLARE OR CELLS  .......................................................................103  
APPENDIX I: GRADING SCALE FOR ASSESSMENT OF VITREOUS CELLS  ............105  
APPENDIX J: AMENDMENT HISTORY  ...........................................................................106  
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING COVID-
[ADDRESS_1144186] OF TABLES  
Table 1:  Treatment Arms with Approximate Number of Subjects ...............................................37  
Table 2:  Laboratory Sampling and Analysis ................................................................................48  
Table 3:  Total Study Blood Volume .............................................................................................52  
Table 4:  Power to Detect a Difference Among [ADDRESS_1144187] OF FIGURES  
Figure 1:  Study Schema ................................................................................................................[ADDRESS_1144188] 202 0 
2. SYNOPSIS  
Study Title  
A Phase 3 , Multic enter, Randomized, Double -Masked, Sham -Controlled Study to Compare the Efficacy and Safety 
of Intravitreal P egcetacoplan  Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary 
to Age -Related Macular Degeneration (AMD)  
Protocol Number, Version , and  Date  
APL 2-304/ Amendment 5/ [ADDRESS_1144189], Dose , and Route of Administration  
• Pegcetacoplan  (also known as APL -2) 
• 15 mg/0.1 mL 
• Intravitreal (IVT) Injection  
Study Arms  
Arm  Abbreviation  Randomization 
Pegcetacoplan 1 5 mg/0.1 mL monthly for 24 months  PM 2 
Pegcetacoplan 1 5 mg/0.1 mL every other month for 24 months  PEOM  2 
Sham monthly for 24 months  SM 1 
Sham every  other  month for 24 months  SEOM  1 
Study Phase and Type  
Phase 3, multicenter, randomized, double -masked, sham -injection controlled  
Number of Subjects and Sites  
• Approximately [ADDRESS_1144190] s 
• Approximately [ADDRESS_1144191] to:  
• Monocular maximum reading speed (study eye), as assessed by [CONTACT_758098] -Vision Reading Test  
(MNREAD) or Radner Reading Char ts (in select countries)  
• Functional Reading Independence (FRI) index score  
• Normal luminance best  corrected visual acuity score (NL- BCVA) in the study eye  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144192] 202 0 
Secondary:  
• To evaluate the efficacy of pegcetacoplan  compared to sham  injection in patients with GA s econdary 
to AMD with respect to : 
o Low luminance best corrected visual acuity score (LL -BCVA) in the study eye  
o Low luminance deficit (LLD) in the study eye  
o Total area of GA lesion(s) in the study eye  
o Monocular critical print s ize (study eye), as assessed by  [CONTACT_758114] 
(in select countries)   
o National Eye Institute Visual Functioning Questionnaire 2 5 Item Version (NEI VFQ -25) 
distance activity subscale score (in select countries)  
o Macular functional response as assessed by [CONTACT_825149]:  
• To evaluate the safety and tolerability of pegcetacoplan  compared to sham  injection in patients with 
GA secondary to AMD as indicated by:  
o Incidence and severity of ocular and systemic treatment -emergent adverse events  
o Incidence of anti -thera peutic antibodies directed against pegcetacoplan  
o Incidence of new active CNV in the study eye  
Exploratory  
• To evaluate the efficacy of pegcetacoplan  compared to sham  injection in patients with GA seco ndary 
to AMD as indicated by:  
o NEI VFQ- 25 composite score  
o NEI VFQ- 25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the binocular maximum reading speed as assessed by [CONTACT_758101] (in select countries)  
o To evaluate the binocular critical print size as assessed by [CONTACT_758102] (in select countries)  
• To evaluate the r elationship between genetic polymorphisms associated with AMD with GA 
progression and response to pegcetacoplan  
• To evaluate the i ncidence of new onset of subclinical CNV in the study eye  
• To assess sensitivity and specificity of a digital reading speed application to detect disease progression 
/ regression  (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect disease 
progression / regression (optional, select sites)  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144193] the same visual acuity, the right 
eye will be selected as the study eye.  
Ocular -specific inclusion criteria apply to the study eye  only, unless otherwise specified.  
1. Age ≥[ADDRESS_1144194] corrected visual acuity of 24 letters or better using Early Treatment Diabetic 
Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent).  
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by [CONTACT_825150] r eading center.  
4. The GA lesion must meet the following criteria as determined by [CONTACT_73475]’s assessment of 
fundus autofluorescence (FAF) imaging at screening:  
a. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas [DA] respectively)  
b. If GA is multifocal, at least [ADDRESS_1144195] be ≥1.25  mm2 (0.5 DA), with the overall aggregate area 
of GA as specified above in  4a. 
c. The entire GA lesion must be completely  visualized on the macula centered image and must be able to 
be imaged in its entirety and not contiguous with any areas of peripapi[INVESTIGATOR_43687].  
d. Presence of any pattern of hyperautofluorescence in the junctiona l zone of GA. Absence of 
hyperautofluorescence (ie, pattern  = none) is exclusionary.1 
5. Adequate clarity of ocular media, adequate pupi[INVESTIGATOR_179995] , and fixation to permit the collection of good 
quality images as determined by [CONTACT_941] i nvestigator.  
6. Meets the following criteria related to microperimetry:  
a. Able to detect fixation target.  
b. Total elapsed time to complete the 10 -2 68-point  exam is ≤[ADDRESS_1144196] be ≤20% .  
d. Subject is willing and able to undertake microperimetry assessment in the opi[INVESTIGATOR_871] .  
7. Female subjects must be:  
a. Women of non– child bearing  potential (WONCBP), or  
b. Women of child bearing  potential (WOCBP) with a negative serum pregnancy test at screening and 
must agree to use protocol defined methods of contraception for the duration of the study and refrain 
from breastfeeding for the duration of the study.  
8. Males with female partners of child bearing  potential must agree to use protocol defined methods of 
contraception and agree to refrain from donating sperm for the duration of the study.  
9. Willing and able to give informed consent and to comply with the study procedures and assessments.  
Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified.  
1. GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy, or  toxic 
maculopathies like plaquenil maculopathy in either eye.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144197] 202 0 
2. Spherical equivalent of the refractive error demonstrating >  6 diopters  o f myopia or an axial length 
>26 mm. 
3. Any history or active choroidal neovascularization (CNV), associated with AMD or any other cause, 
including any evidence of retinal pi[INVESTIGATOR_825129] -OCT imaging and/or fluorescein angiography as  assessed by [CONTACT_941] r eading center. 
4. Presence of an active ocular disease that in the opi[INVESTIGATOR_825130], including but not limited to, uveitis, other macular diseases (eg,  clinically significant epi[INVESTIGATOR_825131] [ERM], full thickness macular hole or uncontrolled glaucoma/ocular hypertension). Benign 
conditions in the opi[INVESTIGATOR_758065].  
5. Intraocular surgery (including lens replacement surgery) wi thin 3 months prior to randomization.  
6. History of laser therapy in the macular region.  
7. Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule 
opacification done at least 60 days prior to screening is not exclusionary. 
8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention 
during the study period or, in the opi[INVESTIGATOR_2511] i nvestigator, could compromise visual function during the 
study period.  
9. Any contraindicati on to IVT injection including current ocular or periocular infection.  
10. History of prior intravitreal injection.  
11. Unable to perform microperimetry reliably in the opi[INVESTIGATOR_871].  
12. Prior participation in another interventional clinical study for i ntravitreal therapi[INVESTIGATOR_825132] (including 
subjects receiving sham).  
13. Prior participation in another interventional clinical study for geographic atrophy in either eye including 
investigational oral medication and placebo.  
14. Participation in any systemic  experimental treatment or any other systemic investigational new drug within 
6 week s or 5 half -lives of the active ingredient (whichever is longer) prior to the start of study treatment. 
Note: clinical trials solely involving observation, over -the-counter  vitamins, supplements, or diets are not 
exclusionary.  
15. Medical or psychiatric conditions that, in the opi[INVESTIGATOR_871], make consistent follow -up over 
the 24- month treatment period unlikely, or would make the subject an unsafe study candidate.  
16. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opi[INVESTIGATOR_758067].  
17. Known hypersensitivity to fluorescein sodium for injection or hypersensitiv ity to pegcetacoplan or any of 
the excipi[INVESTIGATOR_758068].  
Study Design  
This is a 24- month, Phase [ADDRESS_1144198] s across approximately 100 multinational sites . Subjects will be 
screened within 28 days before receiving pegcetacoplan  or sham injection . Upon entry into the  study, subjects will 
be assigned a screening number . Subjects who meet all inclusion and none of the exclusion criteria will return to the 
clinic for randomization and treatment on Visit 2 ( Day 1). At this visit, subjects will be randomized 2:2:1:[ADDRESS_1144199] a n every other month, sham injection monthly, or  sham  injection every  
other  month , respectively . Randomization will be stratified according to GA lesion area at screening (< 7. 5 mm2; ≥ 
7.5 mm2), and presence of CNV in the fellow eye.  
All subjects will be assessed monthly during the first 12 months regardless of treatment regimen. From Month 12 to 
Month 24, subjects will follow the outlined visit schedule ( Appendix A  to Appendix D ) based on treatment 
assignment ( ie, subjects in the monthly groups will be assessed monthly while subjects in the every -other -month  
[EOM] groups will be assessed every  other  month) . The last visit in the study will be at Month 24, approximately 30 
days (monthly treatment group ) or 60 days (EOM treatment group) after the last visit at which investigational 
product is administered.  A t the end of the [ADDRESS_1144200] the option to enroll into a 
separate open -label study.  
Subjects who discontinue study treatment can continue participation in the study and should be encouraged to return 
to the clinical site for as many follow -up visits as they can (with the exception of pegcetacoplan /sham 
administration) . Subjects who wish to fully withdraw from the study before Month 24, should be encouraged to 
complete the early termination visit. 
Endpoints and statistical analysis:  
Endpoints  
Primary Efficacy Endpoint  
• Change from baseline to Month 12 in total area of GA lesion(s) in the study eye (in mm2) based on 
fundus autofluorescence ( FAF) .  
Key Secondary Efficacy Endpoints  
• Change from baseline in m onocular maximum reading speed (study eye), as assessed by [CONTACT_758105] 24 (in select countries)  
• Change from baseline in Functional Reading Independence (FRI) i ndex score, at Month 24.  
• Change from baseline in normal luminance best  corrected visual acuity score (NL- BCVA) at Month 24 
as assessed by [CONTACT_758106] .  
Secondary Efficacy Endpoints  
• Change from baseline in low luminance best corrected visual acuity score (LL -BCVA) at Month 12 
and Month 24 as assessed by [CONTACT_758106] .  
• Change from baseline in low luminance deficit (LLD) at Month 12 and Month 24.  
• Change from baseline at each planned assessment in the total area of GA lesion(s) in  the study eye (in 
mm2) as assessed by [CONTACT_737262] . 
• Change from baseline in monocular critical print size (study eye), as assessed by [CONTACT_825151], at Month 12 and Month 24 (in select countries).  
• Change from baseline in the National Eye Institu te Visual Functioning Questionnaire 25- Item Version 
(NEI VFQ -25) distance activity subscale score at Month 12 and Month 24  (in select sites).  
• Number of scotomatous points assessed by [CONTACT_825152] .  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144201] 202 0 
• Change in macular sensitivity as assessed by [CONTACT_825152].  
Exploratory Endpoints   
• Change from baseline in NEI VFQ -25 composite score at Month 12 and  Month 24.  
• Change from baseline in NEI VFQ- 25 near activity subscale score at Month 12 and Month  24 (in 
select countries) . 
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24 .  
• Binocular maximum reading speed as assessed by [CONTACT_758107] (in 
select countries).  
• Binocular critical print size as assessed by [CONTACT_758108] (in select 
countries) . 
• Relationship between genetic polymorphisms associated with AMD with GA progression and r esponse 
to pegcetacoplan . 
• Incidence of new onset of subclinical CNV in the study eye .  
• Assess sensitivity and specificity of a digital reading speed application to detect disease progression / regression  (optional, select sites) . 
• Assess sensitivity and spe cificity of a digital visual function application to detect disease progression / 
regression  (optional, select sites) . 
Safety Endpoints  
• Incidence and severity of ocular  and systemic treatment -emergent adverse events .  
• Incidence of anti -therapeutic antibodi es directed against pegcetacoplan . 
• Incidence of new active CNV in the study eye.  
Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA lesion(s) in eyes injected with pegcetacoplan , either monthly (PM) or every -other month ( PEOM ), or sham injections . GA lesion area 
(mm
2) as measured by a quantified central reading center based on FAF images . The primary analysis will be the 
comparison of pegcetacoplan , either monthly (PM) or every -other month ( PEOM ) versus the combined 2 sham arms 
(the 2 sham arms will be combined into a single ‘control’ group).  
The null and alternative hypotheses for the primar y efficacy analysis are:  
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM , and  
H0: µS = µ PEOM  vs  H A:  µS ≠ µ PEOM  
Note: here µ indicates each group’s respective mean change from baseline to Month [ADDRESS_1144202] model for longitudinal data will be used to analyze the change from baseline in GA lesion area. The 
model will include treatment, and presence of CNV in the fellow eye as fixed effects; baseline GA lesion area (at 
screening), time (in months) as a factor; as well as the time  × treatment interaction term . All available data up to [ADDRESS_1144203] 202 0 
months will be included in the model for the primary analysis . The mean cha nge  from baseline to 12 months will be 
estimated from the model ( ie, least square [LS] mean) and compared between each of the pegcetacoplan  arms to the 
sham control . For other time poi nt of interes t, LS mean change from baseline will be estimated and compared 
between treatments . Unstructured variance covariance will be used,  
For the analysis of final study data, a similar model including data up to [ADDRESS_1144204] an approximately 5 DMC  data reviews . Allocating an alpha level of 0.0001 for each 
DMC  data review, the alpha level remains for the efficacy analysis at 0.0495 to maintain an overall study alpha of 
0.05.  
The hypothesis testing strategy for the primary and secondary efficacy endpoints will be based on the Gate -keepi[INVESTIGATOR_825133] I error strongly at 2- sided 0.0495 as follow s:  
Step 1. The mean GA lesion growth at 12 months will be compared between the PM group and the Control at 
the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing 
proceeds to Step 2  and Step 3 . If it’s not rejected, the testing procedure stops at this step.  
Step 2. The mean GA lesion growth at [ADDRESS_1144205] 80%  for the comparison in this step.  
Step 3. The mean GA lesion growth at 24 months will be compared between the PM group and the Control at 
the α level of 0.0495 if the null hypotheses are rejected at both Step 1  and Step 2 ; or at the α level of (0.0495 – 
α1) if Step [ADDRESS_1144206] the null hypothesis. If the null hypothesis at this step is r ejected, the α level 
used at this step will be passed down to the next step of testing. If it’s not rejected, the testing procedure stops at this step.  
Step 4 . The prioritization and alpha allocation for the remaining secondary endpoints will be specified in the 
SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the results from 
the primary analysis method:  
• Analyses will be repeated using the mITT and per-protocol sets  
• Primary and secondary endpoints will  also be summarized with no pooling of the  2 sham arms . The 
comparison for pegcetacoplan  and sham injection within each dose regimen ( ie, PM vs SM and PEOM  
vs SEOM) will be conducted  
• Multiple imputation (MI) methods and other sensitivity analyses will be e xplored,  and details will be 
provided in the SAP  
Analysis  for Key Secondary and Secondary Endpoint(s)  
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary endpoint using 
mixed effect model . The binary secondary endpoints will be analyzed using Cochran -Mantel -Haenszel test stratified 
by [CONTACT_94487] . Hypothesis testing for  [ADDRESS_1144207] 202 0 
Subjects will be randomized in a 2:2:1:[ADDRESS_1144208] a mean of 1.47, 1.70 and 2.13 mm2/year for pegcetacoplan  monthly, pegcetacoplan  every -other -month , and 
sham -pooled groups , respectively, as estimated from the results of a Phase  [ADDRESS_1144209] s in each group (ie, a total enrollment of [ADDRESS_1144210] s) 
and the observed annual growth rate in GA lesion area  from Phase  [ADDRESS_1144211] 
99.2% power to show the difference between PM and sham  group and 81.5% power to show the difference between 
PEOM and sham  group using the common standard deviation of 1. [ADDRESS_1144212] analysis of variance , SAS 9.4 . The study power is likely 
larger when utilizing the lon gitudinal data to model the primary endpoint . The actual study power may also vary 
based on the distribution of the strat ification factors ( ie, lesion area at screening, presence of CNV in fellow eye), 
and site enrollment . 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144213]  
CNV  choroidal neovascularization 
CRF (eCRF)  case report form (electronic CRF ) (used interchangeably) 
DA disk area  
DCFP  digital color fundus photography 
DMC data monitoring committee  
EDC  electronic data capture 
EOM  every other month 
ERG  electroretinography 
ERM  epi[INVESTIGATOR_825134] S tudy 
FAF fundus autofluorescence 
FFA/FA  fundus fluorescein angiography or fluorescein angiography 
FRI functional reading independence index  
FSH follicle -stimulating hormone  
GA geographic atrophy 
GCP  Good Clinical Practice  
HCG  human chorionic gonadot ropin 
IB investigator’s brochure 
ICF informed consent form  
 form  
ICH International Council for Harmonis ation  
IEC independent ethics committee  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144214] -A optical coherence tomography angiography 
PEG  polyethylene glycol 
PEG40  polyethylene glycol (40- kDa nominal molecular weight)  
PEOM  pegcetacoplan  every -other- month  
PI [INVESTIGATOR_825135], Inc
Page [ADDRESS_1144215]  operating procedures  
TEAE treatment -emergent adverse event  
t1/[ADDRESS_1144216] 202 0 
4. INTRODUCTION 
4.1. Background  
This study is being conducted as part of a series of studies for the clinical development of 
pegcetacoplan  for advanced Age- related Macular Degeneration (AMD) (neovascular AMD and 
geographic atrophy [GA]). The trial will be conducted in complian ce with this protocol, Good 
Clinical Practice (GCP), and applicable regulatory requirements . The subject population will 
comprise adult male and female subjects with GA secondary to AMD. 
4.1.1. Age-Related Macular Degeneration  
Age-related  macul ar de generation  is the l eading cause of severe vision loss in people over the age 
of [ADDRESS_1144217] the advanced forms of AMD.3 The early signs of AMD (drusen and pi[INVESTIGATOR_211485]) are common in individuals over age 65 and precede the late stage forms, which are 
visually devastating. The late stage forms of AMD are classified into either macular 
neovascularization (neovascular, wet, or exudative AMD) or GA. 
Geographic Atrophy is a disease characterized by [CONTACT_758109][INVESTIGATOR_178712] (RPE) and concurrent atrophy of photoreceptors and choriocapi [INVESTIGATOR_167583].4,5,[ADDRESS_1144218] been demonstrated to influence 
AMD risk, with as many as 5 of these encoded by [CONTACT_758110]. 
Inflammatory processes, especially those mediated by [CONTACT_758111] a key role in AMD.
5 It is thought that these may contribute to loss of choriocapi[INVESTIGATOR_167583], photoreceptors , and 
RPE cells .  
GA is responsible for approximately 20% of all cases of legal blindness in North America ( ie, 
BCVA 20/200 or worse) with increasing incidence and prevalence owing to a higher life 
expectancy.4  While there is treatment for exudative AMD with anti-VEGF therapi[INVESTIGATOR_014], no 
approved therapy exists for GA which is usually bilateral and relentlessly progressive. It 
represents a significant unmet need as it leads to si gnificant visual impairment and affects more 
than 5 million people worldwide.13 
An overview of available information regarding pegcetacoplan  follows below. Further details 
can be found in the pegcetacoplan  inves tigator’s brochure (IB) .26 
4.1.2. Pegcetacoplan 
Pegcetacoplan is a PEGylated cyclic peptide inhibitor of complement C3 . Pegcetacoplan  is 
formed by 2 identical pentadecapeptides  (combining a bioactive cyclic tridecapeptide C3 -
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144219] 202 0 
inhibiting moiety and a 2-amino acid linker) covalently coupled to each end of a linear 40 kDa 
polyethylene glycol (PEG) chain. T here are [ADDRESS_1144220] inhibitor of the complement cascade, a biological process that is part of innate immunity and is involved in 
multiple inflammatory processes . The PEGylation of the molecule imparts slower cl earance from 
the vitreous humor following administration.  
Pegcetacoplan Intravitreal Injection 1 5 mg /0.1 mL will be provided as a 150 mg/ mL sterile 
solution of pegcetacoplan  in stoppered glass vials. Pegcetacoplan is a sterile, isotonic solution in 
acetate -buffer, pH 5.0, containing trehalose. The drug product is packaged in 2R clear Type I 
glass vials with 1 3 mm FluroTec-coated chlorobutyl grey stoppers and sealed with 13 mm 
aluminum/polypropylene flip-off type seals.  
4.1.3. Nonclinical Data  
This section is intended to briefly summarize information on the safety, tolerability,  and PK of 
intravitreal ( IVT), intravenous (IV)  and subcutaneous ( SC) injections of pegcetacoplan . For 
complete and detailed information, refer to the IB. 
As pegcetacoplan  is only pharmacologically active in primates, the pi[INVESTIGATOR_825136]. The safety and tolerability of 
IVT-administered pegcetacoplan has been assessed in a Good Laboratory Practice 
(GLP )-compliant pi[INVESTIGATOR_758072] (9- month) repeat -dose study in cynomolgus monkeys. In 
addition, 2 GLP -compliant 2 -month ocular bridging studies (the first comparing drug substance 
from  2 different CMOs,  the second assessing the safety and tolerability profiles of 3 different 
formulations to support the Phase 3 clinical study) have been conducted in cynomolgus monkeys 
as well . . Pegcetacoplan  was observed to be minimally immunogenic in the 9-month study a s 
evidenced by a lack of circulating antibodies in the majority of monkeys studied. The NOEL for chronic (9-month) IVT dosing was concluded to be >24.8 mg /eye. The results of this 9 -month 
chronic study in cynomolgus monkeys support the safety of chronic IVT injections of pegcetacoplan  at monthly or bimonthly intervals in humans. 
PK assessments included in the chronic (9-month) study revealed serum concentrations of pegcetacoplan  that were approximately dose-proportional [ADDRESS_1144221] IVT dose. The 
serum t
1/2 of IVT -administered pegcetacoplan, determined in a separate PK assessing a 
10 mg /eye dose (in 50 µL), was 10.4 days although the pegc etacoplan  levels measured in the 
serum following infrequent IVT administration are  orders of magnitude lower than 
pharmacological serum levels achieved with SC or IV administration. 
Additional nonclinical  studies in monkeys and rabbits, including assessments of other routes of 
administration (SC and IV), have further defined pegcetacoplan ’s safety profile . . Pegcetacoplan  
has been shown to be generally tolerated through all 3 routes of administration assessed (IVT, 
SC, and IV), with no adverse effects observed in safety pharmacology studies ( in vivo  
cardiopulmonary telemetry and in  vitro  hERG inhibition assay) and genotoxicity studies (Ames, 
in vitro aneugenicity and clastogenicity in TK6 cells, and in vivo  clastogenicity in mouse 
micronuclei) .  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144222] 202 0 
4.1.4. Clinical Data  
The initial safety and tolerability of pegcetacoplan  following IVT administration in humans was 
tested in an open- label, single dose escalation, Phase I clinical study in patients with wet age-
related macular degeneration under protocol POT-CP043014 ([STUDY_ID_REMOVED]). The study was 
conducte d in multiple ophthalmology clinical sites in the US and Australia . A single dose of 
pegcetacoplan  was administered on Day  [ADDRESS_1144223] of care. Three escalating doses of pegcetacoplan  administered IVT 
were studied . Three subjects received 4  mg; 3  subjects received 10  mg, and 7 s ubjects received 
20 mg . No serious adverse events (SAEs) or drug- related adverse events (AEs) of concern were 
observed. It was concluded that administration of a single dose of pegcetacoplan  IVT up to 
20 mg is safe and well  tolerated .  
A Phase 2 study (Protocol POT -CP121614; NCT 02503332) to assess the safety, tolerability,  and 
evidence of activity of multiple intravitreal injections  of pegcetacoplan  in subjects with 
geogr aphic atrophy secondary to AMD has been completed . The study was conducted at multiple 
ophthalmology clinical sites in the US, Australia,  and New Zealand . Subjects were randomized 
in a 2:1:2:1 manner to either receive pegcetacoplan  IVT 1 5 mg  monthly for 12 months; s ham 
IVT monthly for 12 months; pegcetacoplan  IVT 1 5 mg  every other month for 12 months; or 
sham IVT every other month for 12 months.  
This study demonstrated a statistically significant slowing of disease progression at Month 12 at 
the pre specified  alpha of 0.1. P egcetacoplan  administered monthly showed a 29% ( P=.008) 
reduction in the rate of GA lesion growth compared to sham and pegcetacoplan  administered 
every other month showed a 20% ( P=.067) reduction. P egcetacoplan  has been generally well 
tolerated . The most frequently reported AEs  have been related to the injection procedure 
(intravitreal injection), which are common ly found in this type of study. An imbalance in new 
active choroidal neovasculari zation ( CNV) in subjects treated with pegcetacoplan  was observed 
and the risk of developi[INVESTIGATOR_758073] a prior history of 
neovascular AMD in the fellow eye. One subject in the sham arm, 1/81 (1%) was observed to 
have developed new active study eye exudation compared with 2 5/165 (15 %) subjects that 
received pegcetacoplan  IVT injections, 26 subjects in total. Of the 25 pegcetacoplan  treated 
subjects with new active CNV , 18 subjects received PM treatment and 7 subjects received 
PEOM treatment.  
Seventeen of the 25 (68%)  subjects that developed new active study eye CNV had a prior history 
of neovascular AMD in the nonstudy fellow eye. No significant imbalance in history of neovascular AMD in the fellow eye was observed among the 3 arms to explain the imbalance in new exudation observed in study eyes. Visual acuity data did not demonstrate clear differences between subjects developi[INVESTIGATOR_825137]. 
A Phase 1b study (Protocol APL2-103; NCT 03777332) to assess the safety of pegcetacoplan  in 
subjects with GA secondary to AMD and low vision is currently ongoing. This study is being 
conducted at multiple ophthalmology clinical sites across the US. Subjects receive monthly 
treatment with intravitreal pegcetacoplan  for [ADDRESS_1144224] 202 0 
4.1.5. Rationale 
[IP_ADDRESS]. Rationale for Pegcetacoplan for  Treatment of Geographic Atrophy  
The rationale for the use of a complement inhibitor in patients with AMD is based on evidence 
from both human and animal studies. Human biochemical, genetic, and clinical lines of evidence 
indicate that the complement system plays a role in the etiology of AMD . Complement 
components including C3, the membrane attack complex , and complement factor H , are present 
in drusen and basal laminar deposits in eyes from patients with AMD.7,8,9,[ADDRESS_1144225] or B, C3a, C5a, 
SC5b-9 (soluble terminal complement complex) , C3d, and Ba compared to age- matched 
controls.
21,22,23,24  
4.1.6. Dose Selection  
A single dose of 15 mg /0.1 mL  injection administered monthly or EOM for 24  months will be 
tested in this study (see Section  7.3.1). Pegcetacoplan  was well  tolerated in a panel of animal 
toxicology studies. A 9 -month, repeat-dose GLP study in cynomolgus monkeys was conducted 
to evaluate the safety of IVT injections of pe gcetacoplan  at doses up to 24.8 mg /eye at a 
frequency of 1 injectio n every 4 weeks.  
In this pi[INVESTIGATOR_758074], the NOEL was established as >24.8 mg  of pegcetacoplan  delivered intravitreally every 4 week s for 9 months using a 100 µL 
injection . The volume of the human vitreous is approximately 4  mL, which is approximately  
2.7-fold larger than the mean vitreous volume of cynomolgus monkeys, 1.5 mL.
25 Based on the 
difference in vitreous volume between man and cynomolgus and the NOEL defined in nonhuman primates, the human equivalent dose was determined to be 67 mg /eye every 4 week s. 
The dose (15 mg/injection) of pegcetacoplan  that will be evaluated in this clinical study is 
expected to result in drug concentrations approximately 4.5-fold lower that the NOEL observed in cynomolgus monkeys.  
To support appropriate assessments of dose response to pegcetacoplan , pegcetacoplan  is 
administered in  2 different frequencies in the study: monthly and every other month.  
Physician feedback injecting a 200 mg/mL solu tion in the Phase 1 (Study POT-CP043014; 
[STUDY_ID_REMOVED]) trial confirmed that 150 mg/mL is the highest practical concentration that can be 
routinely administered, which set the dose of the Phase 2 trial to 1 5 mg  (ie, 0.1 mL of a 
150 mg/mL solution) . The [ADDRESS_1144226] efficacious in the 
Phase 2 trial. The 1 5 mg  dose given every other month demonstrated slightly less efficacy but 
offers a reduced  treatment burden for patients and physicians.  
4.2. Risk/Benefit  
The Phase 1 (Study POT -CP043014; [STUDY_ID_REMOVED]) and Phase 2 (Study POT-CP121614; 
NCT 02503332) studies provide supporting evidence of a positive benefit-risk profile for the use 
of pegcetacoplan  in treating patients with AMD, specifically patients with GA . These 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144227] 202 0 
prelimin ary res ults of an up to 28% reduction of GA progression rate support the evaluation of 
pegcetacoplan in a Phase [ADDRESS_1144228]  1 dose (15 mg/injection) of pegcetacoplan  as part of these studies. In the Phase 2 
study in patients with GA an imbalance in new exudation in subjects treated with pegcetacoplan  
was observed . Section  4.1.4 provides a summary of the study design and key results from both 
studies. 
The safety monitoring practices employed by [CONTACT_3181] (complete ophthalmologic exam, IOP 
monitoring, OCT, fluores cein angiography, vital signs, hematology, serum chemistry, urinalysis, 
physical exam, vital signs, and AE questioning) are adequate to protect the subjects’ safety. There are also risks associated with the ophthalmic p rocedures required for participants in this 
study. However, these are all standard procedures that are widely performed in ophthalmology. 
In the days following any IVT injection, patients are at risk of developi[INVESTIGATOR_825138] ( eg, endophthalmitis). In recent  studies conducted with pegcetacoplan  
IVT from a single manufacturer, events of transient moderate and severe intraocular 
inflammation have been observed. Other risks of IVT injection include traumatic cataract, retinal 
detachment, increased IOP,  and hemor rhage.  
The amount of blood (See Section  9.16) planned for collection from each subject over the 
[ADDRESS_1144229] 202 0 
5. STUDY OBJECTIVES  
5.1.1. Primary Objective  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patient s with GA 
secondary to AMD assessed by [CONTACT_758112] ( FAF). 
5.1.2. Key Secondary Objectives  
To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with G A 
secondary to AMD with  respect to: 
• Monocular maximum reading speed (study eye), as assessed by [CONTACT_758098]-
Vision Reading  Test  (MNREAD) or Radner Reading Charts (in select countries)  
• Functional Reading Independence (FRI) index score 
• Normal luminance bes t corrected visual acuity score (NL -BCVA) in the study eye  
5.1.3. Secondary Objectives  
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD with  respect to: 
o Low luminance best corrected visual acuity score (L L-BCVA) in the study 
eye  
o Low luminance deficit (LLD) in the study eye 
o Total area of GA lesion(s) in the study eye 
o Monocular critical print size (study eye), as assessed by [CONTACT_758114] (in select countries)   
o National Eye Institute Visua l Functioning Questionnaire 25- Item Version 
(NEI VFQ -25) distance activity subscale score (in select countries)  
o Macular functional response as assessed by [CONTACT_825153]  
5.1.4. Safety Objectives  
• To evaluate the safety and tolerability of pegcetacoplan  compared to sham  injection 
in patients with GA secondary to AMD as indicated by: 
o Incidence and severity of ocular and systemic treatment -emergent adverse 
events  
o Incidence of anti -therapeutic antibodies directed against pegcetacoplan  
o Incidence of new active C NV in the study eye 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144230] 202 0 
5.1.5. Exploratory Objectives 
• To evaluate the efficacy of pegcetacoplan  compared to sham injection in patients with 
GA secondary to AMD as indicated by: 
o NEI VFQ-25 composite score  
o NEI VFQ-25 near activity subscale score (in select countries)  
o Comparison between study eye and fellow eye in change in GA lesion size  
o To evaluate the binocular maximum reading speed as assessed by [CONTACT_825154] (in select countries)  
o To evaluate the binocular critical print size as assessed by [CONTACT_758114] (in select countries)  
• To evaluate the relationship between genetic polymorphisms associated with AMD 
with GA progression and response to pegcetacoplan  
• To evaluate the incidence of new onset of subclinical CNV in the study eye 
• To assess sensitivity and specificity of a digital reading speed application to detect disease progression / regression (optional, select sites)  
• To assess sensitivity and specificity of a digital visual function application to detect 
disease progression / regression (optional, select sites)  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144231] the same visual acuity, the right eye will be selected as the study eye.  
Ocular -specific inclusion criteria apply to the study eye  only, unless otherwise specified. 
1. Age ≥ [ADDRESS_1144232] corrected visual acuity of 24 letters or better using Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts ( approximately 20/320 S nellen 
equivalent). 
3. Clinical diagnosis of GA of the macula secondary to AMD as determined by [CONTACT_825155] c enter.  
4. The GA lesion m ust meet the following criteria as determined by [CONTACT_178842]’s assessment of FAF imaging at screening:  
a. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas [DA] respectively) . 
b. If GA is multifocal, at least [ADDRESS_1144233] be ≥1.25  mm2 (0.5 DA), with the overall aggregate 
area of GA as specified above in 4a. 
c. The entire GA lesion must be completel y visualized on the macula centered image and must be able to 
be imaged in its entirety and not contiguous with any areas of peripapi[INVESTIGATOR_43687].  
d. Presence of any pattern of hyperautofluorescence in the junctional z one of GA . Absence of 
hyperautofluoresce nce ( ie, pattern  = none) is exclusionary.1 
5. Adequate clarity of ocular media, adequate pupi[INVESTIGATOR_179995], and fixation to permit the collection of good quality images as determined by [CONTACT_093].  
6. Meets th e following criteria related to microperimetry:  
a. Able to detect fixation target.  
b. Total elapsed time to complete the 10 -2 68-point  exam is ≤[ADDRESS_1144234] be ≤20% .  
d. Subject is willing and able to undertake microperimetry assessment in the opi[INVESTIGATOR_871].  
7. Female subjects must be: 
a. Women of non–c hildbearing  potential (WONCBP), or  
b. Women of child bearing  potential (WOCBP) with a negative  serum  pregnancy test at screening and 
must agree to use protocol defined methods of contraception for the duration of the study and refrain 
from breastfeeding for th e duration of the study.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144235] agree to use protocol defined 
methods of contraception and agree to refrain from donating sperm for the duration of the 
study. 
9. Willing and able to give informed consent and to comply with the study procedures and assessments.  
6.1.2. Exclusion Criteria  
Ocular specific exclusion criteria apply to the study eye  only, unless otherwise specified . 
1. GA second ary to a condition other than AMD such as Stargardt disease, cone rod 
dystrophy, or toxic maculopathies like plaquenil maculopathy in either eye. 
2. Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >[ADDRESS_1144236] imaging and/or fluorescein angiography as assessed by [CONTACT_171120] . 
4. Presence of an active ocular disease that in the opi[INVESTIGATOR_825139], including but not limited to, uveitis, other macular diseases 
(eg, clinically significant epi[INVESTIGATOR_43691] [ ERM ], full thickness macular hole) or 
uncontrolled glaucoma/ocular hypertension). Benign conditions in the opi[INVESTIGATOR_825140]. 
5. Intraocular surgery (including lens replacement surgery) within 3 months prior to random ization .  
6. History of laser therapy in the macular region. 
7. Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary. 
8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opi[INVESTIGATOR_871], could compromise visual function during the study period.  
9. Any contraindication to IVT injection including current ocular or periocular infection.  
10. History of prior intravitreal injection .  
11. Unable to perform microperimetry reliably in the opi[INVESTIGATOR_871]. 
12. Prior participation in another interventional clinical study for intravitreal therapi[INVESTIGATOR_758066] (including subjects receiving sham). 
13. Prior participation in another interventional clinical study for geographic atrophy in either eye including investigational oral medication and placebo. 
14. Participation in any systemic experimental treatment or any  other systemic 
investigational new drug including within [ADDRESS_1144237] 202 0 
(whichever is longer) prior to the start of study treatment. Note: clinical trials solely 
involving observation, over-the-counter vitamins, supplements, or diets are not 
exclusionary.  
15. Medical or psychiatric conditio ns that, in the opi[INVESTIGATOR_871], make consistent 
follow-up over the 24-month treatment period unlikely, or would make the subject an unsafe study candidate. 
16. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opi[INVESTIGATOR_2511] i nvestigator is clinically significant and not suitable for study participation . 
17. Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the excipi[INVESTIGATOR_758077].  
6.2. Women  of Childbeari ng Potential  
WOCBP a re de fined  as premenopausal women physiologi cally capable of beco ming pregnant. 
6.3. Women of Non childbearing Potential  
WONCBP are defined as women meeting any of the following criteria:  
• Older than 45 years with amenorrhea for > 2 year s or older than 60 year s with 
amenorrhea for > 1 year . Both confirmed by [CONTACT_96879] -stimu lating hormone ( FSH) and 
LH levels.  
• Has undergone hysterectomy, 
• Has undergone bilateral oophorectomy, 
• Has undergone bilateral salpi[INVESTIGATOR_1656]. 
6.4. Approved Methods  of Contraception  
Approved methods of contraception include:  
• Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
o Oral 
o Intravaginal 
o Transdermal  
• Progestogen-only hormonal contraception associated with inhibition of ovulation: 
o Oral 
o Injectable  
o Implantable 
• Intrauterine device  
• Intrauterine hormone- releasing system  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144238] 202 0 
• Bilateral tubal occlusion  
• Vasectomized  partner (provided that partner is the sole sexual partner of the WOCBP 
trial participant and that the vasectomized  part ner has received medical assessment 
of the surgical success) 
• Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatments). Sexual abstinence is only 
accepted when it is the pr eferred and usual lifestyle of the subject. 
Subjects must agree to use an approved method of contraception during the study and [ADDRESS_1144239] may withdraw from the study at any time for any reason without prejudice to his/her future medical care by [CONTACT_8018]. The investigator or sponsor may withdraw the subject at any time ( eg, in the intere st of subject safety) . The investigator is 
encouraged to discuss withdrawa l of a subject from treatment with  the investigational product 
(IP) with the m edical monitor, when possible. 
Subjects who discontinue treatment with the IP can continue participation in the study and 
should be encouraged to return to the clinical site for as many follow-up visits as they can. In the event that a subject terminate s early  from the study, all early termination procedures should be 
performed even if they are outside the allowed study window.  
The reason for termination, date of stoppi[INVESTIGATOR_825141] , all follow -up information and the 
total amount of IP  administered  must be recorded in the case report form (CRF) and source 
documents. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144240], Digital Color Fundus Photograph (D CFP) , Near Infrared 
Reflectance (NIR) , and f luorescein angiography (FA) to provide an objective assessment of 
subject eligibility . Subjects will be randomized 2:2:1:1 to receive treatment with PM, PEOM , 
sham in jection monthly (SM) or sham injection every  other month (SEOM), respectively . 
Table 1 presents the treatment arms along with the approximate number of subjects and 
injections per arm.  
The randomization scheme will be generated and maintained by [CONTACT_456], or designee. Subjec t randomization will be stratified by [CONTACT_758119] (< 7. 5 mm
2; ≥ 7.5 mm2) 
and presence of CNV in the fellow eye (yes; no) . Further details on the randomization 
procedures will be described in the s tatistical analysis plan .  
7.2. Masking and Minimization  of Bias 
The intent of masking is to limit the occurrence of conscious and unconscious bias in the conduct 
and interpretation of the clinical study. Bias could arise from the influence that the knowledge of 
a specific treatment assi gnment may have on the recruitment and allocation of subjects, their 
subsequent care, the assessment of endpoints, the handling of withdrawals, and so on. The 
essential aim of masking, therefore, is to prevent identification of the treatments by [CONTACT_70579] t 
and the masked assessors associated with the conduct of the study until all such opportunit ies for 
bias have passed.  
This is a double- masked study. Designated masked s tudy site staff ( eg, assistant( s), visual acuity  
technicians, OCT technicians, photographers, technicians administering questionnaires, s ubjects , 
reading c enter personnel, the assi gned evaluating physician(s), and the sponsor) will be masked 
to treatment assignment. However, the treating physician and any associated support staff 
involved in performing the intravitreal or sham injections will be unmasked to study treatment. These in dividuals are not allowed to discuss treatment and/or patient outcome with masked study 
staff, including the evaluating physician. The principal investigator [INVESTIGATOR_758079]’ treatment assignment. To prevent bias in treatment assignment, eligible subjects will be randomized using a web-based randomization system. Documentation will be put in place to 
avoid unintentional unmasking during the study. All stu dy roles will be clearly documented on 
the site delegation of authority log and once the roles have been designated and executed, these 
roles should not be switched during the conduct of the study. In unforeseen circumstances, a site 
can contact [CONTACT_758121] a study staff member from the masked role to the unmasked role but not vice versa. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144241] treatment by [CONTACT_758122] ( eg, the subject or his/her physician) is required, an individual investigator (or 
designee) will have the ability to unmask the treatment assig nment for a specific subject and 
share that information with the appropriate parties . All documentation indicating unmasking 
must be retained with the subject’s source documentation in a secure manner. A DMC  will be 
set-up to monitor patient safety and review data. The DMC  will be provided unmasked safety 
data but will be masked to efficacy data unless this data is deemed medically necessary . 
Procedures for DMC  unmasking will be documented in a DMC  Charter .  
For regulatory reporting and if required by [CONTACT_427], the sponsor will unmask study 
treatment for all serious, unexpected adverse reactions that are conside red to be related to study 
drug. Subjects who have had their treatment assignment unmasked secondary to a serious or unexpected AE or medical emergency will no longer receive study treatment. However, they 
should continue to complete as many of the follow-up visits as possible. 
The study unmasking for the primary analysis at 12 months will be limited to the analysis team 
and personnel only on an  as-needed basis . All other personnel in the “masked” role will remain  
masked until the end of study. A document listing out the roles and responsibili ties of the 
individuals participating in the unmasking analysis will be provided prior to the unmasking.  
7.3. Dosage and Administration  
7.3.1. Dose  Levels and Treatment Arms  
After randomization and during the treatment phase beginning at Day  1, all subjects will receive 
a single dose of 15 mg  pegcetacoplan /0.1 mL  or sham injection intravitreally either monthly or 
every other month depending on treatment designation as presented in Table 1 below.  
Table 1:  Treatment Arms with Approximate Number of Subjects  
Treatment Arms  
Pegcetacoplan  15 mg/0.1 mL monthly for 24 months (n= approximately [ADDRESS_1144242] s; 24 pegcetacoplan  
injections)  
Pegcetacoplan 15 mg/0.1 mL EOM for 24 months (n= approximately [ADDRESS_1144243] s; 12 pegcetacoplan 
injections)  
Sham monthly for 24 months (n= approximately [ADDRESS_1144244] s; 24 sham injections) 
Sham EOM for 24 months (n= approximately 100 subjects ; 12 sham injections)  
7.3.2. Treatment Administration   
Only qualified study staff and those delegated the responsibility of study drug administration on 
the delegation of authority log should perform this procedure. All staff should be appropriately 
trained on all procedures prior to performing the procedures. Sites should follow the Visit Schedule  for order of procedures and assessments .  
Administration of study treatment ( pegcetacoplan  or sham) can be done on a separate day from 
the assessment visit if both days fall within the visit window . If this occurs on the randomization 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144245] should be scheduled on time for the next dosing visit. 
7.3.3. Drug  Supplies  
[IP_ADDRESS]. Identity of Investigational Product  
Pegcetacoplan will be supplied as a liquid solution in stoppered glass vials and should be stored 
according to the label. Specific instructions for preparing pegcetacoplan  for the IVT injection 
procedure will be provided in the manual of procedures . Pegcetacoplan Intravi treal Injection 
15 mg /0.1 mL (15 0 mg/mL) is a sterile, isotonic solution of pegcetacoplan  in acetate -buffer, pH 
5.0, containing trehalose . The drug product is packaged in 2R clear Type I glass vials with 
13 mm FluroTec-coated chlorobutyl grey stoppers and sealed with 13- mm 
aluminum/polypropylene flip-off type seals.  
Sham will be provided as empty stoppered glass vials and should be stored according to the 
label .  
[IP_ADDRESS]. Storage  
Vials should be automatically stored as per the instructions until ready for use. Each vial should only be used once. Vials should not be shaken and should be protected from sunlight.  
[IP_ADDRESS]. Accountability  
Pegcetacoplan  drug product and sham vials will be provided to a designee at the study site and 
must be stored in a pharmacy or otherwise locked and secured, at the temperature specified on 
the label . The  drug product supply is accessible only to those individuals authorized by [CONTACT_978]. 
The sponsor will supply sufficient quantities of pegcetacoplan  drug product and sham to allow 
completion of this study. The site should only use the investigational medicina l product provided 
by [CONTACT_758123]. 
Designated  unmasked study staff will provide the study treatments to the subjects in accordance 
with their assigned subject numbers and the randomization schedule. During the study, the 
receipt of the drugs supplied at the clinical site and of study treatment dispensation for each 
subject will be documented in drug accountability records. These drug accountability records are to be kept separate from the patient medical records and other source documents.  
All used vials should be retained by [CONTACT_825156]. At 
the conclusion of the study, any unused IP returned to the sponsor  or designee , or destroyed per 
sponsor instructions, and this will be documented in the drug accountability records. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144246] injection  
procedures will be provided in the manual of procedures. 
Clinic staff  involved in the injection tray assembly, anesthetic preparation, and study drug 
preparation and administration will follow appropriate aseptic techniques to minimize the risk of 
potential AEs  associated with IVT injections.  
Administration of pegcetacoplan  is only allowed if pre injection  IOP ≤ [ADDRESS_1144247]  be performed 
before all pegc etacoplan  injections . This is done by [CONTACT_758125] 30-60 seconds during anesthetic preparation.  
In addition to the procedures outlined in the protocol and manual of procedures ( MOP ), 
adherence to specific i nstitutional policies associated with IVT injections will be observed.  
7.4. Sham Injection Administration  
The procedure for sham injection will be the same as that used for IVT injection until the actual 
injection but no actual inj ection will occur . The inject ing physician will only touch the study eye 
with the blunt end of the syringe. No needle or medication will be injected inside the eye. Detailed instructions on sham injection procedures and post injection  procedures will be pro vided 
in the manual of procedures .  
Subjects randomized to the monthly or every-other-month sham- injection groups will receive 
sham injection monthly or every other  month, respectively. The same assessments will be 
performed as for the subjects in the pegc etacoplan  groups.  
7.5. Concomitan t Therapi[INVESTIGATOR_758080] a participant is receiving at the start of the study, within 30 days 
prior to screening, or that are given for any reason during the study (except for routine 
medications given for ocular procedures required by [CONTACT_760], such as topi[INVESTIGATOR_15413]) must be recorded in the source documents and CRF including start and stop date and time, dose, 
route, and indication. In addition, all invasive intraocular procedures from the previous [ADDRESS_1144248] also be recorded in the source document s and CRF  including start and stop dates. Surgical 
anesthetics, paramedical or alternative therapi[INVESTIGATOR_014] ( eg, acupuncture, herbal supplements) should 
also be recorded in the source documents and CRF within 30 days prior to screening. 
Metoclop ramide or other agents to prevent nausea induced by [CONTACT_758126].  
7.5.1. Treatment of New Exudation Related to Active Choroidal Neovascularization in 
the Study Eye  and/or Fel low Eye 
The suspected onset or presence of new exudation related to active CNV secondary to AMD in 
the study eye and/or fellow eye must be documented in the source documents and CRF. If the 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144249] 202 0 
investigator suspects new exudation related to active CNV in the study eye based on fundus 
examination and/or OCT findings ( eg, subretinal fluid, intraretinal fluid, cystoid macular edema, 
serous pi[INVESTIGATOR_6678]), a fluorescein angiography and Optical Coherence 
Tomography Angiography (OCT- A; select sites on ly) must also be captured following the 
imaging protocol procedure. All images, as outlined above, must be sent to the reading center. The reading center will provide a report indicating whether or not evidence of active, exudative AMD is present or absent , based on the images sent for a ssessment.  
The determination about initiation of anti- VEGF treatment for the exudation related to active 
CNV is the sole responsibility of the investigator. Treatment with anti-VEGF should start after the report is received by [CONTACT_758127], with the exception of cases with clear 
evidence of disease activity (eg, ; subretinal hemorrhage, extensive subretinal fluid and/or edema, 
and/or presence of subretinal hyperreflective material) that, in the opi[INVESTIGATOR_1101] t he investigator, 
may have a detr imental visual impact if not treated immediately .  
If it is determined that the subject requires anti-VEGF therapy, ranibizumab or aflibercept should 
be selected and administered by [CONTACT_758128] (unmasked) physician. Ranibizumab should be given monthly and aflibercept every other month after 3 monthly loading doses. The frequency 
of aflibercept can be changed to monthly if deemed necessary by [CONTACT_093], however the 
physician should refrain from using as- needed treatment (PRN) or treat and extend protocols. 
Every effort should be made to use the same anti-VEGF therapy for a subject during the course of the study and all treatments should be documented in the CRF. 
If anti -VEGF therapy is administered in the study eye on the same day as an pegcetacoplan  (or 
sham) injection, the anti-VEGF therapy shall be administered first and the pegcetacoplan  or 
sham  injection shall occur at least 3 0 min utes after the anti -VEGF injection and only if the IOP 
is ≤[ADDRESS_1144250] perform both procedures. If the anti -VEGF therapy is given 
on a separate day from the pegcetacoplan  administration, either the masked or the unmasked 
physician may perform this injection .  
Treatment with anti- VEGF is allowed in the fellow eye . The treatments for the fellow eye can be 
administered accordin g to the site’s standard protocol for CNV treatment. Any treatments or 
therapi[INVESTIGATOR_758081] 5 year s of screening and while on study should be 
recorded as a concomitant medication.  
7.5.2. Prohibited Therapi[INVESTIGATOR_758082] a determ ination regarding patient continuation of therapi[INVESTIGATOR_758083] . Therapi[INVESTIGATOR_758084]/exclusion criteria are 
prohibited as specified. 
7.5.3. Endophthalmitis Treatment  
Endophthalmitis cases  must be reported as SAEs. The decision to treat a participant for 
endophthalmitis or suspected endophthalmitis will be guided by [CONTACT_825157] (as applicable). A culture s ample should be 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144251] 202 0 
performed prior to making a decision on treatment. The treatment method (pars plana vitrectomy 
vs intravitreal injection of antibiotics ) and choice of antimicrobial agents are also at the 
discretion of the physician and should follow current standard practice patterns . The decision to 
use IVT steroids ( eg, dexamethasone) for the treatment of endophthalmitis is also at the 
discretion of the physician. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144252] is approximately 25 months 
(from the beginning of the screening period through completion of the Month 24 visit). After 
completion of the 24-month treatment period, subjects will be offered entry into a separate open-label study. 
8.1. Study Visit Schedule  
Below is a condensed description of the study visits and the procedures and examinations that will be performed . Please refer to the Visit Schedule  in Appendix A  to Appendix D  for a detailed 
schedule of procedures/assessments for the monthly and EOM visit schedules. Additional safety 
assessments not listed in this section or the flow chart may be performed if considered necessary 
at the discretion of the investigator. 
8.1.1. Screening Period —Within 28 Days P rior to Randomization/ T reatment (Day –28 
to –1) 
[IP_ADDRESS]. Visit  1—All S ubjects  
Note: All ophthalmic procedures (including imaging) are to be performed on both eyes, except 
where specified .  
Before any study-specific procedures are performed, the purpose and nature of the study should be explained and the patient should read, sign, and date the Institutional Review 
Board/Independent Ethics Commi ttee (IRB/I EC)-approved Informed Consent Form (ICF) . The 
individual obtaining consent from the patient and a witness, if applicable, should also sign and 
date the ICF . Once the patient has signed the ICF, a screening number should be assigned to the 
patien t. Demograp hic information, significant medical/surgical history within the previous 
5 year s, invasive ocular procedures within the previous 5 year s, and concomitant medications 
used within 30 days prior to screening should be collected (including vitamins and all over -the-
counter as well as prescription medications) . Complete smoking/ tobacco history should also be 
collected.  
Subject eligibility should then be determined by [CONTACT_758130]/exclusion criteria and 
the study eye should be selected. Pr ior to the administration of fluorescein, blood and urine 
should be collected for safety labs (including blood for human chorionic 
gonadotropin/follicle -stimulating hormone/luteinizing hormone [ HCG/FSH/LH] , if applicable) 
and vital signs along with a physical examination including weight and height should be performed.  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, 
aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and intraocular pressure ( IOP) measurement . Normal luminance BCVA should be performed prior to dilating the 
eyes. Images should be captured as outlined in the Visit Schedule (FAF, NIR, DCFP, FFA) and 
forwarded to the reading center for determination of eligibility if applicable.  
Mesopic microperimetry should be performed on both eyes post dilation of the eyes and 
forwarded to the reading c enter.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144253] 202 0 
8.1.2. Randomization/ Initial Treatment —Day  1—Within 28 Days of S creening  
[IP_ADDRESS]. Visit  2—All G roups  
At this visit, all inclusion/exclusion  criteria should  be reviewed prior to randomization and 
dosing, including the determination of eligibility by [CONTACT_171120] . Subjects will be 
randomized using the Interactive Web Response (IWR) System. A complete ophthalmic exam 
including slit lamp  exam of the cornea,  iris, anterior chamber, lens,  and aqueous reaction (cells 
and flare), dilated fundus exam of the vitreous and retina, and IOP measurement will be performed and imaging collected as per the Visit Schedule. 
All assessments should be performed on the same day. All study visits should be scheduled and 
projected based on the Day  1 visit date.  
Blood should be drawn for anti -pegcetacoplan  antibodies.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Read ing Charts [ in select countries ]). Subjects at select sites will be trained 
on how to use the home-based digital applications for visual function and reading speed if the subject decides to participate in this portion . This training mus t occur after completion of all 
functional tests (NL -BCVA, LL -BCVA) . Tests completed using the digital application  at select 
sites (optional) should be completed prior to dilating the eyes but after completion of all 
functional tests and quality of life me asures (NL -BCVA, LL -BCVA, MNREAD or Radner 
Reading Charts [ in select countries] , NEI VFQ-25, and FRI). The subject should be instructed to 
take the electronic device home and to complete the digital application weekly on the same day each week, if possible. The quality of lif e measures (NEI VFQ -25 and FRI) should be 
administered by [CONTACT_258426] .  
Imag ing should be performed including FAF, SD- OCT, OCT -A (select sites), endothelial cell 
count (select sites)  and NIR  and sent to the reading c enter for evaluatio n.  
Study drug or sham  injection should be performed by [CONTACT_825158]  9.16. A follow-up phone call should be scheduled with the subject 4 ± 2 days after 
randomization Day  1 to assess for any AEs .  
8.1.3. Treatment Phase—24 Months   
[IP_ADDRESS].  Months 1 -12 
[IP_ADDRESS].1. Visits  3-14 (Monthly  and Every -Other Month  Group)  
During this phase, there will be clinic visits every month. Dosing and assessments will occur monthly in the monthly pegcetacoplan  and s ham injection treatment arms . Dosing will occur 
every  other month in the EOM pegcetacoplan  and s ham injection treatment arms, however, the 
subjects will return monthly for assessments (with no dose given).  
A complete ophthalmic exam including slitlamp  exam of the cornea, iris, anterior chamber, lens,  
and aqueous reaction (cells an d flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and imaging collected as pe r the Visit Schedule.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144254] 202 0 
Blood will be drawn for safety labs, anti -pegcetacoplan  antibodies, and genotypi[INVESTIGATOR_007] (Month 2 
only) prior to the administration of fluorescein as per the Visit Schedule . Samples will be 
collected for the clinical repository for those subjects that consent to this portion.  
Prior to dilating the eyes, all functional tests will be performed (NL -BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [ in select countries ]). Tests completed using the digital 
application  at select sites (optional) will be completed prior to dilating the eyes but after 
completion of all functional tests and quality of life measures (NL -BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [ in select countries ], NEI VFQ -25, and FRI). At select 
sites t he subject should be instruct ed to take the electronic device home and to complete the 
digital application weekly on the same day each week, if possible. The subject will be instructed 
to bring back the electronic device for the visits specified in the schedule of events. The quality 
of life measures (NEI VFQ -25 and FRI) will be administered by [CONTACT_258426] .  
Mesopic microperimetry should be performed on both eyes (where specified) post dilation of the eyes and forwarded to the reading c enter.  
Imag ing will be performed i ncluding FAF, FFA, SD-OCT, OCT -A (select sites), endothelial cell 
count (select sites)  and NIR  and sent to the reading c enter  for evaluation per the visit schedule.  
Study drug or sham injection should be performed by [CONTACT_825159]  9.16. A follow-up phone call should be scheduled with the subject as outlined in the 
schedule of events.  
In the event that a subject is early terminated from the study, all early termination procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
shoul d make every effort to have the subject complete as many follow -up visits as possible.  
[IP_ADDRESS]. Months  13-24  
[IP_ADDRESS].1. Visits  15-26 (Monthly Group) and 15-20 (Every- Other- Month Group)  
During this phase, clinic visits will follow treatment designation ( ie, the monthly subje cts will 
return monthly for dosing and assessments and the EOM  group will return EOM  for dosing and 
assessments) . At select sites, s ubject s will complete the home -based digital assessments  weekly 
during this period.  
A complete ophthalmic exam including sl itlamp  exam of the cornea, iris, anterior chamber, lens,  
and aqueous reaction (cells and flare), dilated fundus exam of the vitreous and retina, and IOP 
measurement will be performed and imaging collected as per the Visit Schedule.  
Blood should be drawn for safety labs , genotypi[INVESTIGATOR_007], and anti -pegcetacoplan  antibodies prior to 
the administration of fluorescein as per the Visit Schedule . Samples will be collected for the 
clinical repository for those subjects that consented to this portion.  
Prior to dilating the eyes, all functional tests should be performed (NL- BCVA, LL -BCVA, and 
MNREAD or Radner Reading Charts [in s elect countries ]). The quality of life measures (NEI 
VFQ -25 and FRI) should be administered by [CONTACT_258426].  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144255] 202 0 
Mesopic microperimetry should be performed on both eyes (where specified) post dilation of the 
eyes and forwarded to the reading c enter.  
Imag ing should be performed including FAF, FFA, SD -OCT, OCT -A (select sites), endothelial 
cell count (select sites) and NIR  and sent to the r eadin g center for evaluation  per the visit 
schedule.  
IVT (or sham) injection should be performed by [CONTACT_825160]  9.16. 
In the event that a subject is early terminated from the study, all early termination  procedures 
should be performed even if they are outside the allowed study window.  
If the subject would like to discontinue dosing but is amenable to continuing in the study, the site 
should make every effort to have the subject complete as many follow-up visits as possible.  
The completion of the 24-month study period occurs approximately 30 days (monthly t reatment 
group) and approximately 60 days (EOM treatment group) after the last visit at which 
investigational product ( IP) is administered . The period following last dose of IP is sufficient to 
evaluate the safety of pegcetacoplan based on its half -life in  the vitreous; further details can be 
found in the pegcetacoplan IB. At the end of the 24-month study period, subjects will have the 
option to enroll in a separate open-label study. 
8.1.4. Early Termination  Visit  
A list of all assessments to be performed at the early termination visit can be found on the Visit 
Schedule. All subjects who end the study early for any reason must complete the e arly 
termination visit, however all efforts should be made to have the subject return for as many 
follow-up visits as possible even if dosing does not occur. All  ophthalm ic procedu res are to be 
performed on BOTH EYES . 
8.1.5. Unscheduled Visit s 
If a subject returns to the clinical site before their next scheduled visit for an assessment of an 
AE or at the request of the physician, all safety assessments should be performed and  any 
additional assessments as deemed medically necessary by [CONTACT_825161].   
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144256] 
source docum entation .  
9.2. Demographic Information/ Medical/ Surgical  History  
Demographic information will be collected from all subjects including but not limited to date of birth, race/ ethnicity  (where locally perm itted) . All significant medical conditions and surgeries 
within the past [ADDRESS_1144257] including chronic and ongoing 
conditions. Any history or current use of tobacco is to be collected. 
9.3. Ocular History/ Ocular Procedures   
Ocular history within the previous 5 year s should be collected and recorded for all subjects. The  
history should include any significant previous ocular surgeries, procedures and/ or medications or treatments used for these conditions.  
9.4. Vital Signs  
Vital signs  consist of body temperature, respi[INVESTIGATOR_697], blood pressure (systolic and diastolic), 
and heart rate measurements .  
On injection visits, vital signs w ill be measured prior to dosing. Vital signs should be taken with 
the patient in a seated position afte r resting for 5 minutes. Vital signs will be measured before 
venipuncture. 
9.5. Physical Examination  
A physical exam will be performed and should include but should not be limited to an evaluation 
of the eyes, ears, nose, throat, lymph nodes, head, and neurological fu nction . A patient’s height 
and weight should also be measured at screening . If any abnormalities are noted at screening, the 
PI, or designee, should determine the clinical significance of the finding and whether this will 
pose any safety risk to the subject. Any changes from baseline should be noted and the clinical 
significance assessed . Any new, clinically significant, findings should be documented as AEs .  
9.6. Laboratory Analysis of B lood and U rine 
Collection of blood and urine will occur at the study site and the samples will be shipped to a 
central laboratory for analysis . All samples (including urine) should be collected prior to 
treatment and F FA/OCT -A assessments (if applicable) . Procedures for the collection and 
processing of blood and urine are provided in the laboratory manual.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144258] 202 0 
Table 2 presents the laboratory and urine analysis that will be performed.  
Table 2:  Laboratory Sampling and Analysis 
Hematology Chemistry  Urinalysis  Other 
Hemoglobin  
Hematocrit  
Red blood cell count   
White blood cell count 
with differential  
Platelet count  Blood urea nitrogen  Creatinine  
Bilirubin (total, direct 
and indirect)  
Albumin  Alkaline phosphatase  Aspartate 
aminotransferase  
Alanine aminotransferase  
Creat ine kinase  
Glucose 
Electrolytes (sodium, 
potassium, chloride, bicarbonate) pH 
Specific gravity  
Protein  
Glucose Ketones Biliru bin 
Blood Nitrite  
Urobilinogen Leukocyte esterase  Genotypi[INVESTIGATOR_758085]-pegcetacoplan  Ab  
Human chorionic 
gonadotropin
a  
Follicle -stimulating 
hormoneb  
Luteinizing hormoneb  
 
 
a Serum Pregnancy Test (ie, HCG) will be performed for females of childbearing potential at screening only.  
b FSH and LH will be performed for postmenopausal females at screening only.  
The principal investigator, or designee, must review the results of the screening visit clinical 
laboratory tests (including any retest results) and confirm that these results do not show evidence 
of any medical condition that would make study participation inappropriate. The principal 
investigator, or designee, should also assess any changes from baseline at the follow-up visits and the final visit. Clinically significant laboratory values are to be recorded as AEs . 
9.7. Genotypi[INVESTIGATOR_825142] . 
A whole -blood sample will be collected for genetic marker analysis. These samples will be 
collected only for those subjects who consent to this analysis .  
These samples  will be stored as per the clinical repository  guidelines outlined in Section  9.[ADDRESS_1144259] -reported efficacy of pegcetacoplan  and changes 
in quality of life over time . Questionnaires will be translated into the appropriate language for 
each country or region. 
9.9.1. The National Eye Institute Visual Functioning Questionnaire 25 -Item Version  
(NEI -VFQ)  
The NEI-V FQ is an interviewer-a dmin istered questionnaire designed to a ssess patient-r eported 
visual function (Appendix E). T he NEI-VFQ is to be administered by [CONTACT_661578]. It is a 25-
item questionnaire with a composite score and covers 12 domains of functional health s tatus and 
well-being (general health, general 
vision, ocular pain, near activities (select countries),  distance 
activities (select countries), social functioning, mental health, role difficulties, dependency, 
driving, color vision, and peripheral vision). Scoring yields 12 subs cales based on the 12 
domains covered in the questionnaire. T hese scales are scored from 0 to 100 with higher scores 
indicating better visual function. The recall period is not specified; however, it is important that 
the patient uses the same recall period each time the questionnaire is administered throughout 
their participation in the study.  
9.9.2. The Functiona
l Reading Independence  (FRI) Index 
The FRI will be interviewer -administered and is an individualized assessment of functional 
reading independ ence ( Appendix F ). The questionnaire has [ADDRESS_1144260] corrected visual acuity (including best  corrected visual acuity  under low luminance 
[LL-BCVA ]) will be measured at each visit as per the visit schedule by [CONTACT_128841]. The 
study staff performing visual acuity should be masked to the treatment  assignment. Best  
corrected visual acuity testing will be assessed on ETDRS chart starting at a d istance of [ADDRESS_1144261] 202 0 
9.11. Minnesota Low -Vision Reading (MNREAD) Test or Radner Reading 
Charts (in select countries)   
MNREAD Test or Radner Reading Charts ( Appendix G ) should be adminis tered first 
monocularly for both eyes and then binocularly. The Manual of Operations should be referenced 
for a list of versions that sh ould be administered  based on country. These tests should be 
administered prior to dilating the eyes. 
9.12. Home -Based Functional  Digital Applications  (optional,  select sites)  
In addition to in-clinic assessments, visual function and reading speed will al so be evaluated 
using applications on an electronic device. Subjects who decide to participate in this portion will 
be trained on how to use the digital applications during the Day  1 visit and will complete the 
assessments using the digital application in the clinic at Day  1, Months 1-3, Month 6, 12, 18, 
and 24. In-clinic assessments on the digital application should be completed after completion of 
all functional tests and quality of life measures prior to dilating the eyes (NL -BCVA, LL -BCVA, 
MNREAD or Radner Reading Charts [in select countries], NEI VFQ 25, and FRI).  
Subjects will also take home the electronic device to complete visual function and reading speed assessments weekly beginning at Day  1. Subjects should be instructed to complete the 
assessments on the same day each week and at approximately the same time of day each week, if possible. 
9.13. Complete  Ophthalmic Exam  
The comp lete ophthalmic exam will consist of the following: 
• External examination of the eye and adnexa.  
• Routine screening for eyelids/pupil responsiveness (including ptosis, abnormal pupil 
shape,  unequal pupi[INVESTIGATOR_8324], abnormal reaction to light , and afferent pupi[INVESTIGATOR_1396] d efect).  
• Slitlamp  examination (cornea, anterior chamber, iris, lens, aqueous reaction [ cells and 
flare]). Please see Appendix H  for grading scales.  
• Dilated f undus exam including evaluation of retina and vitreous ( ie, posterior segment 
abnormalities, retinal hemorrhage/detachment, and vitreal hemorrhage density and 
vitreous cells) . Vitreal hemorrhage density and vitreous cells grading scales are 
outlined in Appendix I .  
• IOP measurement —A measurement  of intraocular pressure will be conducted using 
either Tono- Pen or Goldmann applanation tonometer as outlined in the MOP. This 
should be performed prior to dilating the eyes and the same method should be used for all measurements in the same subject throu ghout the study. 
9.14. Ocular  Imaging and Microperimetry   
The following ocular images will be obtained and sent to the reading center as outlined in the visit schedule . A reading c enter manual  along with training materials will be provided to all sites  
which wil l provide information on standardized procedures for the collection, storage,  and 
transmission of all images . Prior to any images being taken at the site, site personnel must be 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144262] be certified and 
validated by [CONTACT_825162] c enter . Only trained and certified site staff delegated the responsibility 
of image collection should perform this task. O cular images obtained as part of this study are: 
• Digital Color Fundus Photographs  
• Fluorescei n Angiography  
• Spectral Domain Optical Coherence Tomography imaging  
• Fundus Autofluorescence (Heidelberg Spectralis Instrument)  
• Near  Infrared Reflectance  
• Endothelial Cell Count (Specular Microscopy) : Select sites only  
• Mesopic Microperimetry of the study eye only (at screening, performed on both eyes)  
o To account for the learning curve of this test, the patient is allowed up to 3 
attempts to meet the criteria for this portion  
• Optical Coherence Tomography Angiography (OCT -A): Select sites only   
If a patien t misses a visit during which ocular images should have been taken, the images should 
be collected at the next scheduled study visit. 
In the event that a subject is suspected to have new active CNV in the study eye and/or the 
fellow eye, an SD-OCT  and FFA using the protocol specified procedures should be performed 
and sent to the reading center to confirm the diagnosis ( Section 7.5.1). In addition, in select sites, 
OCT -A should also be captured according to the study imaging protocol and sent to the reading 
center .  
9.15. Postinjection A ssessment  
The study eye will be assessed after the int ravitreal injection of pegcetacoplan  or sham  to ensure 
that the injection procedure and/or the study medication have not endangered the health of the eye. The initial postinjection  assessments should be done within [ADDRESS_1144263] injection and 
include a gross assessment of vision (light perception, hand motion). If the subject passes the 
gross vision test, he/she can be released from t he clinic . If the subject does not pass the gross 
vision test, IOP must be measured at that time . Additional IOP measurement must be taken 
approximately every 30 minutes thereafter until IOP ≤[ADDRESS_1144264] is able to be 
released from the clinic.  
All subjects receiving an anti -VEGF (ranibizumab or aflibercept) and pegcetacoplan /sham 
injectio n on the same day, should have the IOP measured prior to and after the anti- VEGF 
(prepegcetacoplan ). The second injection  (pegcetacoplan/sham ) can only be given if the  
IOP ≤ [ADDRESS_1144265] can 
only be released from the clinic if the IOP is ≤[ADDRESS_1144266] who develops a significant and sustained raise in IOP (>30 mm  Hg) after any 
injection, should be monitored according to the investigator ’s clinical judgment and may 
undergo additional procedures and measurements of IOP beyond those specified in the protocol 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144267] 
will remain at the site and will be treated according to the physician’s clinical judgment.  
9.16. Blood Volume for Study Assessments  
Table 3:  Total Study Blood Volume 
Assay  Number of time 
points  Approxima te 
volume per time 
point * (mL)  Appr oximate 
sample volume 
over course of 
study (mL)—all 
groups  
Anti-pegcetacoplan antibodies  9 2 18 
*Hematology 8 4 32 
**Chemistry (incl. HCG/LH)  8 5 40 
FSH/LH (postmenopausal women 
only) - 5 - 
Genotypi[INVESTIGATOR_758087] 1 8 8 
Clinical repository (select sites a nd 
only subjects that consent to clinical repository) 5 14 70 
Total blood volume   168 a 
Abbreviations:  HCG=human chorionic gonadotropin; FSH=follicle -stimulating hormone ; LH=luteinizing hormone  
a Represents the standard collection volume planned over the duration of the study, actual volume may vary by 
[CONTACT_758133].  
* Volume will vary slightly b etween regions and analyzing labs based on the standard methodology. 
** In some regions, may be included in the chemistry sample based on local methodology . 
 
9.17. Samples for Clinical Repository ( Optional, Select Sites)  
Apellis intends to apply genomic research across the pegcetacoplan  development program to 
explore how genomic variations may affect the clinical parameters associated with and response 
to pegcetacoplan . Select sites will be asked to collect additional whole-blood samples and 
derivatives thereof in a centrally administered facility for the long -term storage of human 
biologic specimens. The collection and analysis of these specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for subjects in the future. Specimens for the Genetic 
Biorepository will be collected from subjects who give speci fic consent to participate in this 
optional research only and this will only be done at a select group of sites.  
Specimens will be used to achieve the following objectives: 
• To study the association of biomarkers with efficacy, AEs , or disease progression 
• To increase knowledge and understanding of disease biology 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144268] 202 0 
• To study drug response, including drug effects and the processes of drug absorption 
and disposition  
• To develop biomarker or diagnostic assays and establish the performance characteristics of these assays  
Future research may suggest other genes, gene categories, proteins, etc. as candidates for 
influencing not only response to pegcetacoplan  but also susceptibility to AMD for which 
pegcetacoplan  may be evaluated . Thus, this additional genomic research may involve the future 
study of additional unnamed genes or gene categories, but only as they relate to AMD disease susceptibility and drug action.  
9.17.1. Approval by [CONTACT_825163] s amples to the c linical repository is contingent upon the 
review and approval of the exploratory research and the c linical repository portion of the N by 
[CONTACT_25733]’s IRB or IEC and, if applicable, an appropriate regulatory body. If a site has not been 
granted approval for c linical repository sampling, this section of the protocol ( Section  9.17) will 
not be applicable at that site.  
9.17.2. Sample  Collection  
The following samples will be collected for research purposes, including but not limited to research on 
dynamic (non inherited ) biomarkers related to AMD and related diseases, pegcetacoplan , and signaling 
pathways related to AMD and the complement pathway: 
• Residual whole-blood clinical genotypi[INVESTIGATOR_71307] 
• 14-mL whole-blood sample collected  at the specified time  points 
For all samples, dates of consent and specimen collection should be recorded on the associated 
clinical repository page of the eCRF. For sampling procedures, storage conditions, and shipment 
instructions, se e the laboratory manual. 
All collected specimens will be destroyed no later than 1 5 years after the date of final closure of 
the clinical database. The c linical repository storage period will be in accordance with the 
IRB/EC- approved I CF and applicable law s (eg, health autho rity requirements).  
9.17.3. Confidentiality and Data Ownership  
Patient medical information associated with c linical repository specimens is confidential and 
may only be disclosed to third parties as permitted by [CONTACT_941] I CF (or separate authorization for use 
and disclosure of personal health information) signed by [CONTACT_102], unless required by [CONTACT_2371]. 
Data derived from c linical repository specimen analysis on individual subjects will generally not 
be provided to the subjects or to study investigators unless required by [CONTACT_2371] . The aggregate results 
of any research conducted using c linical r epository specimens will be available in accordance 
with the effective Apellis policy on study data publication. Any inventions and resulting patents, improvements, and/or know-how originating from the use 
of the c linical repository data will become and remain the exclusive and unburdened property of 
Apellis, including the right to sell, license , or assign the invention to another entity.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144269] 202 0 
9.17.4. Consent to Participate in the Clinical Repository  
The I CF will contain a separate section or separate I CF that will address participation in the 
clinical repository. The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the c linical repository. Subjects 
will be told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period. Subj ects who decline to participate in the 
clinical r epository can still participate in this clinical study . The investigator should document 
whether the patient has given consent to participate by [CONTACT_63412] c linical repository 
Research Sample Informed Consent eCRF . In the event of a c linical repository participant’s 
death or loss of competence, the participant’s specimens and data will continue to be used as part 
of the c linical r epository research.  
9.17.5. Withdrawal From the Clinical Repository  
Subjects who give consent to provide c linical repository specimens have the right to withdraw 
their specimens from the clinical repository at any time for any reason. If a patient wishes to 
withdraw consent to the testing of his or her specimens, the inves tigator must inform the sponsor 
in writing of the patient’s wishes using the c linical r epository Patient Withdrawal Form and, if 
the study is ongoing, must enter the date of withdrawal on the Clinical Repository Research Sample Withdrawal of Informed Conse nt eCRF . The patient will be provided with instructions 
on how to withdraw consent after the study is closed. A patient’s withdrawal from this study does not, by [CONTACT_5071], constitute withdrawal of specimens from the c linical repository. Likewise, a 
patient’s  withdrawal from the c linical repository does not constitute withdrawal from this portion 
of the study. 
9.17.6. Monitoring and Oversight 
Clinical Repository specimens will be tracked in a manner consistent with GCP by a 
quality -controlled, auditable, and appropriately validated laboratory information management 
system to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the I CF. Apellis monitors and auditors will have 
direct access t o appropriate parts of records relating to patient participation in the c linical 
repository for the purposes of verifying the data provided to Apellis. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by [CONTACT_825164] c linical repository samples. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144270] 202 0 
10. SAFET Y EVALUATIONS   
Any clinically significant abnormalities persisting at the end of the study/ early withdrawal or 
end of the post treatment  phase will be followed by [CONTACT_43727] a 
clinically stable endpoint is reached . The study includes a number of evaluations to monitor 
safety including monitoring of AEs , post injection  monitoring, laboratory and urine sampling, 
physical examination, and vital signs.  
10.1. Data Monitoring Committee  
An external, independent data monitoring c ommittee  (DMC) will be formed with the purpose of 
reviewing all data across the conduct of the study on an ongoing basis. The DMC  will follow a 
charter that will outline the frequency of meetings and the roles and responsibilities of all members . The DMC  will meet at the beginning of the study and approximately every [ADDRESS_1144271] and/or in response to an open 
question from the study personnel or revealed by [CONTACT_825165]. All identified AEs must be recorded and described on the appropriate AE or SAE page of the eCRF. 
Fluctuating or nonsignificant changes in laboratory values do not necessarily qualify for AE 
recording but are still collected and re corded via the appropriate eCRF form , if applicable . If 
these changes in laboratory values are linked to a diagnosis, this diagnosis should be reported as 
an AE, esp ecially if the diagnosis constitutes an SAE or leads to discontinuation of 
administration o f IP. 
11.2. Recording Adverse Events  
Adverse events and SAEs will be collected from the signing of the consent form until the last  
visit or early termination  visit, [ADDRESS_1144272] IP administration for the EOM treatment groups. 
Any events that occur prior to dosing will be categorized as pretreatment events; events occurring after dosing w ill be recorded as treatment- emergent adverse events ( TEAEs ) (start date 
of dosing and, therefore, categorization of the event will be dependent on randomization 
assignment). 
For each AE, the investigator will evaluate and report the onset date (and time i f applicable), 
resolution date (and time if applicable), intensity, causality, action taken, serious outcome, and 
whether or not it caused the subject to discontinue the study. 
If possible, the outcome of any AE that caused permanent discontinuation or was present at the 
end of the
 study should be reported, particularly if the AE was considered by [CONTACT_758136]. Subject
s experiencing AEs that cause interruption or discontinuation of IP , 
or those experiencing AEs that are present a t the last visit or early termination  visit should 
receive follow -up as appropriate. 
All SA Es must be reported to the sponsor/Apellis Safety via eCRF within 24 hours of becoming 
aware of the event, whether or not the event is deemed treatment -related. If the electronic data 
capture (EDC) system is not operational (or for paper-based study[ies]), the site must complete the paper SAE form and email to immediately and  also within [ADDRESS_1144273] 202 0 
Adverse events will be coded in accordance with the Medical Dictionary for Regulatory 
Activities (MedDRA). If known, the diagnosis of the underlying illness or disorder should be 
recorded, rather than its individual symptoms. 
11.3. Reporting Adverse Events  
The sponsor has the responsibility to inform concerned health authorities, ethic committees, and 
investigators about suspected unexpected serious adverse reactions in line with GCP guidance and applicable regulatory requirements. 
If required, specific SAEs should be reported to the concerned ethic committees in compliance 
with local requirements   
11.3.1. Relationship of Events to Study Treatment  
All AEs that occur during this study will be recorded. The investigator will review each event and assess it s relationship to study treatment (definitely related, possibly related, unlikely related, 
not related, unknown). The date and time of onset, time relationship to drug dosing, duration, and outcome ( recovered/ resolved, recovered/resolved  with sequelae, recovering/resolving, not 
recovered/not resolved, fatal, or unknown) of each event will be noted.  
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study treatment: 
Defin itely 
Related  Event or laboratory test abnormality, with plausible time relationship to drug intake 
Cannot be explained by [CONTACT_825166] (pharmacologically, pathologically)  
Event definitive pharmacologically or phenomenologically ( ie, an objective and specific 
medical disorder or a recognized pharmacological phenomenon) Re-challenge satisfactory, if necessary  
Possibly 
Related  Event or laboratory test abnormality, with reason able time relationship to drug intake  
Could also be explained by [CONTACT_825167], with a time to drug intake that makes a relationship 
improbable (but not impossible) 
Disease or other drugs provide plausible explanations  
Not Related  Event or laboratory test abnormality, is plausibly related to the participant’s clinical state, 
underlying disease, or the study procedure/conditions 
Time rela tionship to drug intake makes a relationship unreasonable 
Other obvious causes for event or laboratory test abnormality exist 
Unknown Report suggests an adverse event, however, cannot be judged at this time because 
information is insufficient or contradic tory 
More data for proper assessment is needed, or additional data is under examination 
11.3.2. Severity  of Events  
The following definitions should be considered when evaluating the severity of AEs and SAEs: 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144274] 202 0 
Mild  Asymptoma
tic or mild symptoms; clinical or diagnos tic observations only; intervention 
not indicated. 
Moderate Minimal, local or non invasive intervention indicated; limiting age -appropriate 
instrumental ADL  a. 
Severe  Medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care ADLb. 
Note : An experience may be severe but may not be serious, eg, severe headache).  
Abbreviation: ADL=activities of daily living  
A semi colon indicates ‘or’ within the description of the gra de. 
a Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
b Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
11.4. Serious Adverse  Events  
An SAE is any AE or suspected adverse reaction that , in the view of either the investigator or 
sponsor, results in any of the following outcomes: death; life -threatening; inpatient 
hospi[INVESTIGATOR_233003] ; a persistent or significant incapacity 
or substantial disruption of the ability to conduct normal life functions; or a congenital 
anomaly/birth defect.  
Important medical events that may not result in death, be life- threatening *, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in the above definition.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_059] ; or the development of drug dependency or drug abuse. 
*Life -threatening is defi ned as an AE or suspected adverse reaction, which in the view of either 
the investigator or sponsor places the subject at immediate risk of death as it occurred . It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. 
Unexpected Adverse Event 
An AE is considered “unexpected” if it is not listed in the Reference Safety Information section of the IB. 
11.5. Treatment and Follow-up of A dverse Events  
AEs (whether serious or nonserious), including cl inically significant abnormal laboratory test 
values, will be evaluated by [CONTACT_758137]/or followed up until the symptoms or value(s) return to baseline or are clinically st able. Treatment of AEs will be performed by 
[CONTACT_758138], either at the clinical site or at a nearby [CONTACT_2360][INVESTIGATOR_9487] . When appropriate, medical tests and/or examinations will be performed to 
document resolution of the eve nt(s).  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144275] 202 0 
AEs continuing after completion of the study will be followed up by [CONTACT_825168]. If possible, the outcome of any AE that caused discontinuation 
from the study or was present at the end of the study should be reported, particularly if the AE was considered by [CONTACT_151705]. 
11.6. Pregnancy  
Although pregnancy is not an AE, all pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or disease state) occurring with a female subject or the female p artner of a male subject, must be followed to conclusion to determine their outcome and 
are considered immediately reportable events.  
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Apellis Safety within 24 hours of the investigator’s awareness using the paper Pregnancy Report Form. 
The Pregnancy R eport Form shall be signed and dated by [CONTACT_668910] . 
The investigator must follow the subject until completion of the pregnancy and must report the outcome of the pregnancy (eg, delivery, termination, etc.) and neonatal status up to [ADDRESS_1144276] 
normal life functions (fo rmerly referred to as disabilities), congenital anomalies, or birth defects. 
In the event of an abnormal outcome, an SAE Report Form will be required. 
11.7. Disease  Progression  
Normal progression or worsening of the medical condition under study ( eg, vision loss due to the 
progression of GA in either eye ), by [CONTACT_5071], does not necessarily constitute an AE  unless the 
change can be reasonably attributed to an action of the test article and  not only to its lack of 
efficacy . Disease progression that requires an intervention ( eg, administration of IVT anti- VEGF 
agents for neovascular AMD ) should be recorded as an AE  in the eCRF .  
11.8. Withdrawal  
Participants may choose to discontinue from treatment or to completely withdraw from this study for any reason at any time without penalty or prohibition from enrolling in other clinical protocols. 
Participants wishing to withdraw from the study completely will be offered an early termination 
visit. This ear ly termination visit will include the examinations outlined in  Section  8.1.5. 
Participants wishing to discontinue treatment but willing to continue with other study procedures, will return to the clinical site for follow -up vis its, as per protocol, until Month 24. 
Additional information on subject discontinuation is provided in Section 6.5. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144277] 202 0 
12. DATA MANAGEMENT AND STATISTICAL  CONSIDERATIONS  
12.1. Data Collection  
The investigators’ authorized site personnel must enter the information required by [CONTACT_64760]. A study monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered on the CRF will be addressed by [CONTACT_1746]. 
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting .  
12.2. Clinical Data Management  
Data are to be entered into a clinical database as specified in the contract research organization’s  
data management plan . Quality control and data validation procedures are applied to ensure the 
validity and accuracy of the clinical database.  
Data are to  be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to the clinical database, and all corrections are documented in an auditable manner.  
12.3. Statistical Analysis Process  
The study will be analyzed by [CONTACT_10196].  
The statistical analysis plan (SAP) will provide the statistical methods  and definitions for the 
analysis of the efficacy and safety data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, IP exposure, and prior and con comitant medications . The SAP will also include a 
description of how missing, unused, and spurious data will be addressed.  
To preserve the integrity of the statistical analys is and study conclusions, the SAP will be 
finalized prior to database lock . All statistical analyses will be performed using SAS  (SAS 
Institute, Cary, NC [ZIP_CODE]). 
12.4. Planned Interim Analysis and Data Safety Monitoring Committee  
No interim analysis is planned for this study. During the study, patient safety will be monitored 
on a continuous basis by [CONTACT_941] m edical m onitor until the last patient completes his or her last 
scheduled study assessment. 
An independent D MC will also be established to provide an ongoing, independent review and 
assessment of the safety data, and to safeguard the interests and  
safety of the participating patients in the study . The ongoing review of SAEs and other 
responsibilities of the DMC  will be described  in the DMC  Charter.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144278] 202 0 
The overall T ype I (alpha) error rate for the study will be 0.05. To accommodate DMC  data 
reviews, the alpha available for efficacy hypothesis testing will be reduced by 0.[ADDRESS_1144279] .  
12.5. Sample Size Calculation and Power Considerations  
Subjects will be randomized in a 2:2:1:[ADDRESS_1144280] a mean of 1.47, 1.70 and 2.13 mm2/year for 
pegcetacoplan  monthly, pegcetacoplan  every -other -month, and sham -pooled groups, 
respectively, as estimated from the results of a Phase [ADDRESS_1144281] s in each group ( ie, a total enrollment of 
[ADDRESS_1144282] s) under different alpha values and standard deviations. The approximation is 
calculated using PROC POWER one- way analysis of variance, SAS 9.4. The study power is 
likely larger when utilizing the longitudinal data to model the primary endpoint. The actual study power may also vary based on the distribution of the stratification factors ( ie, lesion area at 
screening, presence of CNV in fel low eye), and site enrollment.   
Table 4:  Power to D etect a  Difference Among  [ADDRESS_1144283] 
deviation (mm2) Alpha  
(2-sided)  Power for a true mean of 1.47, 1.70, and 2.13 mm2/year for 
PM, PEOM , and sham , respectively  
PM vs sham  PEOM  vs sham  Overall  
(among 3 groups) 
1.25 0.0495  > 99.9%  92.9%  99.9%  
1.25 0.0248  99.9%  88.2%  99.7%  
1.40 0.0495  99.7%  86.5%  99.3%  
1.40 0.0248  99.3%  79.4%  98.6%  
1.50 0.0495  99.2%  81.5%  98.4%  
1.50 0.0248  98.4% 73.1%  97.0%  
Abbreviations: PM = pegcetacoplan monthly;  PEOM  = pegcetacoplan every other month.  
12.6. Statistical Analysis Set s  
The safety set  will consist of all subjects who receive any amount of IP. 
The intent -to-treat (ITT) set will include all randomiz ed subjects . Subjects will be analyzed in 
the treatment arm assigned at randomization with the  2 sham treatment arms being combined 
into a single ‘control’ group.  
The modified ITT (mITT) set  will include all randomized subjects who receive at least [ADDRESS_1144284] 202 0 
The per-protocol (PP) set  will include all ITT subjects who follow the protocol without any 
major deviation(s) that could i mpact the integrity of the data . A detailed description of the 
reasons for exclusion from the PP population will be included in the statistical analysis plan 
(SAP).  
12.7. Efficacy Analyses  
The primary , secondary, and exploratory efficacy analys es will be perform ed using the I TT set 
and presented by [CONTACT_1570]. 
12.7.1. Primary Efficacy Analysis 
The primary efficacy endpoint is the change from baseline to Month 12 in the total area of GA 
lesion(s) in eyes injected with pegcetacoplan , either monthly (PM) or every -other month 
(PEOM ), or sham injections. GA lesion area (mm2) as measured by a quantified central reading 
center based on FAF images . The primary analysis will be the comparison of pegcetacoplan , 
either monthly (PM) or every -other month ( PEOM ) versus the combined 2 sham arms ( the 2 
sham arms will be combined into a single ‘control’ group). 
The null and alternative hypotheses for the primary efficacy analysis are: 
H0: µS = µ PM   vs  H A:  µ S ≠ µ PM, and  
H0: µS = µ PEOM vs  H A:  µ S ≠ µ PEOM  
Note: here µ indicates each group’s respective mean change from baseline to Month [ADDRESS_1144285] model for longitudinal data will be used to analyze the change from baseline in 
GA lesion area. The model will include treatment  and presence of CNV in the fellow eye as 
fixed effects; baseline GA lesion area ( at screening) , time (in months) as a factor ; as well as the 
time × treatment interaction term. All available data up to 12 months will be included in the 
model for the primary analysis . The mean change from baseline to 12 months will be estimated 
from the model ( ie, least square [LS] mean) and compared between each of the pegcetacoplan  
arms to the sham control . For other time point of interest , LS mean change from baseline will be 
estimated and compared between treatments . Unstructured variance covariance will be used . 
For the analysis of final study data, a similar model including data up to [ADDRESS_1144286] an approximately 5 DMC  data 
reviews . Allocating an alpha level of 0.0001 for each DMC  data review, the alpha level remai ns 
for the efficacy analysis at  0.0495 to maintain an overall study alpha of 0.05. 
The hypothesis testing strategy for the primary and secondary  efficacy endpoint s will be based 
on the Gate-keepi[INVESTIGATOR_758089] I error strongly at 2-sided 0.0495 as follows:  
Step 1. The  mean GA lesion growth at 12 months will be compared between the PM group 
and the Control at the α level of 0.0495. If the null hypotheses of no difference between groups in this step is rejected, the testing proceeds to Step 2 and Step 3 . If it’s not rejected, 
the testing procedure stops at this step.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144287] 80% for 
the comparison in this step. 
Step 3. The  mean GA lesion growth at 24 months will be compared between the PM group 
and the Control at the α level of 0.0495 if the null hypotheses are rejected at both Step 1  and 
Step 2 ; or at the α level of (0.0495 – α1)  if Step [ADDRESS_1144288] the null hypothesis. 
If the null hypothesis at this step is rejected, the α level used at this step will be passed down 
to the next step of testing. If it’s not rejected, the testing procedure stops at this step.  
Step 4. The prioritization and alpha allocation for the remaining secondary endpoints will be 
specified in the SAP.  
The following sensitivity and supportive analyses will be performed to evaluate the robustness of the results from the primary analysis method: 
• Analyses will be repeated using the mITT and PP sets  
• Primary and secondary endpoints will also be summarized with no pooling of the 2 
sham arms . The comparison for pegcetacoplan  and sham injection within each dose 
regimen (ie,  PM vs SM and PEOM  vs SEOM) will be conduct ed 
• Multiple imputation methods and  other sensitivity analys es will be explored, and 
details will be provided in the SAP 
12.7.2. Secondary  Efficacy Analysis 
The key secondary and secondary endpoints will be analyzed in the same fashion as the primary 
endpoint using mixed effect model. The binary secondary endpoints will be analyzed using Cochran -Mantel -Haenszel test stratified by [CONTACT_94487] . Hypothesis 
testing for 3 key secon dary endpoints will be performed in the order specified. The SAP will 
provide more details on multiplicity adjustment and the approach for alpha spending among the endpoints.  
Key Secondary Efficacy Endpoints  
• Change from baseline in maximum monocular reading speed (study eye), as assessed 
by [CONTACT_758140] 24 (in select countries)  
• Change from baseline in FRI index score, at Month 24. 
• Change from baseline in NL-BCVA at Month 24 as assessed by [CONTACT_758106].  
Secondary Ef ficacy Endpoints 
• Change from baseline in LL-BCVA at Month 12 and Month 24 as assessed by 
[CONTACT_758106] .  
• Change from baseline in LLD at Month 12 and Month 24. 
• Change from baseline at each planned assessment in the total area of GA lesion(s) in 
the study eye (in mm2) as assessed by [CONTACT_737262] . 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144289] 202 0 
• Change from baseline in monocular critical print size (study eye), as assessed by 
[CONTACT_758114], at Month 12 and Month 24 (in select countries).  
• Change from baseline in the NEI VFQ -25 distance activity subscale score at Month 
12 and Month 24 (in select countries) .  
• Number of scotomatous points assessed by [CONTACT_825169].  
• Change in macular sensitivity as assessed by [CONTACT_825170]. 
12.7.3. Exploratory Efficacy Analysis 
Summary statistics will be provided for the following exploratory endpoints:  
• Change from baseline in NEI VFQ-25 composite score at Month 12 and Month 24.  
• Change from baseline in NEI VFQ-25 near activity subscale score at Month 12 and Month 24 (in select countries) . 
• Comparison between study eye and fellow eye in change in GA lesion size from baseline to Month 12 and Month 24.  
• Binocular maximum reading speed as assessed by [CONTACT_758141] (in select countries) .  
• Binocular critical print size as assessed by [CONTACT_758142] (in select countries) . 
• Relationship between genetic polymorphisms associated with AMD wi th GA 
progression and response to pegcetacoplan . 
• Incidence of new onset of subclinical CNV in the study eye.  
• Assess sensitivity and specificity of a digital re ading speed application to detect 
disease progression / regression (optional, select sites).  
• Assess sensitivity and specificity of a digital visual function application to detect 
disease progression / regression (optional, select sites).  
12.8. Safety Analyses  
Adverse events will be collected from the time of the first study drug administration until a 
subject completes the study or discontinues prematurely. Treatment -emergent adverse events are 
defined as those AEs that develop or worsen after the first dose of study medication and up to 
[ADDRESS_1144290] 202 0 
subjects reporting SAEs will also be tabulated . Adverse event summaries will be presented for 
each treatment group separately .  
Adverse events will be summarized by [CONTACT_130813], and separate tabulations also will 
be produced for related AEs (those considered by [CONTACT_758143]), 
SAEs , and discontinuations due to AEs . Vital signs data a nd findings from physical and 
ophthalmologic examinations will be tabulated for changes over time on study. Laboratory parameters will be summarized for changes across study by [CONTACT_74305]. Separate 
summaries will be prepared for systemic (nonocular ) and ocular AEs, with events in the study 
eye and nonstudy eye summarized separately  
12.8.1. Anti -Therapeutic Antibodies   
Data on anti-therapeutic antibodies ( ATAs ) directed against pegcetacoplan  will be summarized 
by [CONTACT_825171] .  
12.8.2. Death   
Patient deaths and primary cause of death will be summarized .  
12.8.3. Ocular  Assessments  
Descriptive summaries will be generated for  ocular assessments, such as VA and IOP. 
12.9. Handling of Missing Data  
All efforts will be made to minimize missing data . A full description of the imputation methods 
will be provided in the SAP.  
12.10.  Visit Windows  
Analysis visits will be derived with windows for the monthly visits to assess the primary 
endpoint. Baseline is defined as the date of randomization . If [ADDRESS_1144291] visit to the target day will be used as that analysis visit; if [ADDRESS_1144292] of the Study  
This research will be carried out in accordance with the protocol, applicable regulations, the 
ethical principles set forth in the Declaration o f Helsinki, and the ICH Harmonized Tripartite 
Guidance for Good Clinical Practice, E6 , R1 (ICH GCP).  
13.2. Institutional Review Board/Ethic Committee  
The study protocol, any amendments to the protocol, ICF , the I B, and other study- specific 
information will be re viewed and approved by [CONTACT_1201]/IEC. The study will not be initiated until 
the IRB/IEC  has approved the protocol or a modification thereof. All records pertaining to 
IRB/IEC submission and approval should be kept in the site’s regulatory files and sponsor’s Trial Master File.  
The IRB/IEC must be constituted and operate in accordance with the principles and requirements described in ICH Guidance E6 and national and local regulations as deemed appropriate. 
13.3. Subject Information and Consent  
The principal investigator , or designee, is responsible for obtaining an informed consent. A 
written informed consent, in compliance with ICH Guidance E6, must be obtained from each subject  at the screening visit,  prior to performing any study- related procedures.  
The purpose of the study, the procedures to be carried out, and the potential hazards will be described to the subjects in nontechnical  terms . The subject will be given sufficient time to 
consider the study’s implications before deciding to participate in the study. The  subject and/or 
legal guardian will be required to sign and date an ICF and will be assured that they may withdraw from the study at any time without jeopardizing their medical care . The PI [INVESTIGATOR_758090], signed informed consent for study participation in the subject’s medical record and shall provide the subject and/or legal guardian with a copy of the signed consent. 
If there are any changes/amendments to the approved protocol, which may directly affect the 
subject’s decision to continue participation in the study, the ICF shall be amended to incorporate 
the changes to the protocol and the subject must re- sign the IRB/IEC approved amended ICF.  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144293] Access to Source Data/Documents  
The principal investigator , or de signee,  must maintain, at all times, the primary records (ie,  
source documents) of each subject’s data for data verification . Examples of source documents 
are medical records, laboratory reports, study drug records, and printed CRF pages that are used 
as the source.  
The investigator will permit trial- related monitoring, audits, and inspections by [CONTACT_131494]/or its designee, IRB/IEC, and the regulatory agencies at any time during the study. The investigator will ensure that the auditor is allowed direct access to the source data, medical 
records, eCRF s, and the site’s regulatory file for the study and any other pertinent information.  
14.2. Quality Control and Quality Assurance  
This study is to be performed in full compliance with the protocol, GCP, and applic able 
regulatory requirements. The principal inves tigator, sponsor, and/or its designee are responsible 
for ensuring that the study staff receive appropriate training on the protocol, study procedures, and any other relevant information.  
Quality assurance and quality control systems are implemented and maintained using written Investigative site, sponsor and/or designee Standard Operating Procedures (SOPs) to ensure that 
the study is conducted and data are generated, documented (recorded), and reported in 
compliance with the protocol, GCP, and the applicable regulatory requirement(s) and local laws, rules, regulations. 
Quality control checks will be applied at each stage of data handling ( eg, edit checks) to ensure 
that all data are reliable and have been processed correctly.  
14.3. Monitoring  
On-site monitoring will be performed by [CONTACT_456]’s designee for the duration of the study. 
The monitor will ensure that the study is conducted, recorded,  and reported in accordance with 
the protocol, SOPs, GCP, and the appl icable regulatory requirements . The monitor will verify the 
accuracy and completeness of the eCRF entries, source documents, and other study- related 
records against each other. The inves tigator , or designee, will provide direct access to source 
data/documents for study- related monitoring . It is important that the investigator and the 
investigator site staff are available at these visits . The monitor will record the date of each visit 
together with a summary of the status and progress of the study. Proposed actions will be 
documented in writing to the investigator. 
14.4. Data Handling and Record Keepi[INVESTIGATOR_558750] i nvestigator must maintain all documentation related to this study . All essential documents 
(as defined in the ICH Guideline E6 and applicable local regulations ) and the data generated in 
connection with this study, together with the original copy of the final report, will be retained for at least [ADDRESS_1144294] 
elapsed since the formal discontinuation of clinical development of the IP. These documents 
should be retained for a longer period if required by [CONTACT_155610]. 
It is the responsibility of the sponsor to inform the investigator/ institution as to when these 
documents no longer need to be retained. 
14.5. Protocol Ame ndments  
Any amendments to the study protocol deemed necessary as the study progresses will be 
discussed between sponsor and the investigator. The investigator will not implement any changes 
to the protocol without an agreement by [CONTACT_941] s ponsor and prior review and documented 
approval/favorable opi[INVESTIGATOR_5698]/IEC of an am endment, except where necessary to 
eliminate immediate hazards to study subject or when the changes involve only logistical or 
administrative aspects of the study ( eg, change in staf f, telephone numbers).  
Changes resulting in amendments will be made jointl y between the sponsor and the investigator 
and must be confirmed in writing. Amendment(s) will be approved and signed off in the same way as the protocol.  
14.6. Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH M2 Expert 
Working Group), the final report will be written according to the ICH E3 Guideline (Structure 
and Content of Clinical Study Reports). 
14.7. Finance and Insurance  
Finance and insurance will be addressed in a Clinical Trial Agreement between the s ponsor and 
the investigator/ institution . 
14.8. Publication Policy  
The data generated for this study are considered confidential information and are the property of the sponsor. All study  information provided to the PI [INVESTIGATOR_758092] a third party without the prior written consent of the sponsor.  
Apellis will endeavor to publish the results of all qualifying, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are perceived as positive, neutral, or negative. Additionally, Apellis ad heres to external guidelines 
(eg, Good Publication Practices 2) when forming a publica tion steering committee, which is 
done for large, multicenter Phase 2-[ADDRESS_1144295] undergo appropriate technical and 
intellectual property review, with Apellis  agreement to publish prior to release of information. 
The review is aimed at protecting the sponsor’s proprietary information existing either at the 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144296] 202 0 
commencement of the study or generated during the study. To the extent permitted by [CONTACT_38927], the investigator will own (or share with other authors) the copyright 
on his/her publications. To the extent that the investigator has such sol e, joint,  or shared rights, 
the investigator grants the sponsor a perpetual, irrevocable, royalty- free license to make and 
distribute copi[INVESTIGATOR_10161]. 
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral, or other form.  
Subject to the terms of the paragraph below, the investigator shall have the right to publish the study results, and any background information provided by [CONTACT_822102], or necessary for other scholars to verify such study 
results . Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish and shall be given to the sponsor for review at least [ADDRESS_1144297] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication of the compi[INVESTIGATOR_38865]. If such a multicenter publication is not s ubmitted to a 
journal for publication by [CONTACT_10209] 18-month period after conclusion, abandonment, or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter study publication of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section . The investigator must, however, 
acknowledge in the publication the limitations of the single- site data being presented.  
Unless otherwise required by [CONTACT_10210], or the forum in which it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards . Participation as an investigator does not confer any rights to authorship of 
publications. 
14.9. ClinicalTrials.gov  
This study wi ll be listed with ClinicalTrials.gov.  
14.10.  Termination of Study  
The sponsor reserves the right to suspend or discontinue this study for administrative and/or safety reasons at any time. The investigator reserves the right to discontinue dosing subjects at 
any t ime for safety reasons .  
 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144298] of fundus autofluorescence patterns in  age- related macular degeneration . American 
journal of ophthalmology. 2007;143(3): 463-472. 
2. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through 
the year 2050: the potential impact of new treatments . Archives of ophthalmology . 
2009;127(4):533-540. 
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalen ce of age-related macular degeneration in 
the [LOCATION_002] . Archives of ophthalmology . 2004;122(4):564-572. 
4. Holz FG, Strauss EC, Schmitz -Valckenberg S, van Lookeren Campagne M . Geographic atrophy: 
clinical features and potential therapeutic approaches . Ophthalmology. 2014;121(5):1079-1091. 
5. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate CA. Measuring geographic atrophy in 
advanced age- related macular degeneration. Investigative ophthalmology & visual science. 
1999;40(8):1761-1769. 
6. Sunness JS, Gonza lez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity 
loss in the geographic atrophy form of age- related macular degeneration . Ophthalmo logy. 
1999;106(9):1768-1779. 
7. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach  to the etiology of age -
related macular degeneration . Proceedings of the National Academy o f Sciences of the United 
States of America . 2002;99(23):[ZIP_CODE]-[ZIP_CODE]. 
8. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement 
regulatory gene  factor H (HF1/CFH) predisposes individuals to age- related macular degeneration . 
Proceedings of the National Academy of Sciences of the [LOCATION_002] of America . 
2005;102(20):7227-7232. 
9. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low 
inflammatory reactions involved in exudative age -related macular degeneration? Morphological 
and immunhistochemical analysis of AMD associated with  basal deposits. Graefe's archive for 
clinical and experimental ophthalmology = Albrecht von Graefe s Archiv fur klinische und 
experimentelle Ophthalmologie . 2008;246(6):803-810. 
10. Mullins RF, Russell SR, Anderson DH, Hageman GS . Drusen associated with aging and age-
related macular degeneration contain proteins common to extracellular deposits associated w ith 
atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB journal : official 
publication of the Federation of American Societies fo r Experimental Biology . 2000;14(7):835-
846. 
11. Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, F arrer LA . Complement factor H 
polymorphism and age -related macular degeneration . Science. 2005;308(5720):421-424. 
12. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-
related macular degeneration . Science . 2005;308(5720):419-421. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144299] 202 0 
13. Klein RJ, Zeiss C, Chew EY, et al . Complement factor H polymorphism in age- related macular 
degeneration. Science. 2005;308(5720):385-389. 
14. Maller J, George S, Purcell S, et al . Common variation in three genes, including a noncoding 
variant in  CFH, strongly influences risk of age- related macular degeneration . Nature genetics. 
2006;38(9):1055-1059. 
15. Seddon JM, Yu Y, Mille r EC, et al . Rare variants in CFI, C3 and C9 are associated with high risk 
of advanced age- related macular degeneration . Nature  genetics. 2013;45(11):1366-1370. 
16. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age- related macular 
degeneration. The New England journal of medicine. 2007;357(6):553-561. 
17. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk 
of age -related macular degeneration . Nature genetics. 2013;45(7):813-817. 
18. Fritsche LG, Chen W, Schu M, et al . Seven new loci associated with age- related macular 
degeneration. Nature genetics. 2013;45(4):433-439, 439e431-432. 
19. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 
(C2) genes is associated with age- related macular degeneration . Nature genetics. 2006;38(4):458-
462. 
20. Horie -Inoue K, Inoue S. Genomic aspects of age- related macular degeneration . Biochemical and 
biophysical research communications . 2014;452(2):263-275. 
21. Hecker LA, Edwards AO . Genetic control of complement activation in humans and age related 
macular degeneration . Advances in experimental medicine and biology. 2010;703:49-62. 
22. Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement 
in humans and age- related macular degeneration . Human molecular genetics. 2010;19(1):209-
215. 
23. Machalinska A, Dziedziejko V, Mozolewska-Pi[INVESTIGATOR_825143] K, Karczewicz D, Wiszniewska B, 
Machalinski B . Elevated plasma levels of C3a complement compound in the exudative form of 
age-related macular degeneration . Ophthalmic research . 2009;42(1):54-59. 
24. Scholl HP, Charbel Issa P, Walier M, et al . Systemic comp lement activation in age -related 
macular degeneration . PloS one. 2008;3(7):e2593. 
25. Leeds JM, Henry SP, Bistner S, Scherrill S, Williams K, Levin AA . Pharmacokinetics of an 
antisense oligonucleotide injected intravitreally in monkeys. Dru g metabolism and disposition: 
the biological fate of chemicals . 1998;26(7):670-675.  
26. Fleckenstein  M, Mitchell P, Freund KB , et al. The Progression of Geographic Atrophy Secondary 
to Age- Related Macular Degeneration . Ophthalmology . 2018; 125(3):369-390. 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144300] images, near infrared reflectance, fluorescein angiograms, and fundus photographs w ill be performed for the study eye only on days where 'SE' is specified 
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next schedul ed visit. If new active CNV is suspected, SD-OCT , FFA and OCT -A (select sites) images 
must be collected and sent to the r eading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_825172] a gross assessment of vision (finger -
counting, hand-motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
shoul d be performed . IOP should be ≤ [ADDRESS_1144301] the site . If necessary, anti glaucomatous  medication can be given to lower the  IOP. If IOP is  
>[ADDRESS_1144302] and IOP is ≤30 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept mus t be performed first . The pre - and  post - anti-VEGF IOP val ues must be measured and recorded on the eCRF.  
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 3) to col lect any information on any 
safety concerns, decrease in vi sion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescripti on and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144303]'s participation in 
the study.  
S. In addition to the time points indicated on the stud y schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye . 
T. Administration of pegcetacoplan  or sham  can be done on separate days from  the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the r andomizatio n visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144304] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD-OCT , FFA , and OCT -A (selected sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_758147] a gross assessment of vision (finger -
counting, hand motion, then light perception when applicabl e). If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤[ADDRESS_1144305] the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is 
>[ADDRESS_1144306] and IOP is ≤ 30 mm Hg. Note: if 
the study eye is treated with a  ranibizumab o r aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or 
aflibercept must be performed first . The pre - and post - anti-VEGF IOP values must be measured and recorded on the eCRF. 
Q. Start ing at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocula r symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by [CONTACT_11581] t within [ADDRESS_1144307]'s participation in 
the study .  
S. In addition to the time points indicated on the study schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the  study  eye.  
T. Administration of pegcetacoplan  or sham can be done on separate days from the assessment visit if both days fall within the visit window . Admin istration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144308] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will b e performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image cap ture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit. If new active CNV is suspected, SD-OCT , FFA , and OCT -A (selected sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_758147] a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤ [ADDRESS_1144309] the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP is 
>[ADDRESS_1144310] and IOP is ≤30 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab or  
aflibercept must be performed first . The pre - and post - anti-VEGF IOP valu es must be measured and recorded on the eCRF . 
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, decrease in vis ion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescriptio n and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144311]'s participation in 
the study .  
S. In addition to the time points indic ated on the study schedule,  OCT -A should be performed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye. 
 T. Administration of pegcetacoplan  or sham can b e done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If thi s occurs on the randomizati on visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144312] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is specified  
and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD -OCT , FFA , and OCT -A (selecte d sites)  
images should be collected and sent to the reading center for analysis.  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_758147] a gross assessment of vision (fing er-
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry  
should be performed . IOP should be ≤ [ADDRESS_1144313] the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP is 
>[ADDRESS_1144314] and I OP is ≤30 mm Hg. 
Note: if the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham), the treatment with ranibizumab 
or aflibercept must be performed first . The pre - and post - anti-VEGF IOP values must be measured and recorded on the eCRF . 
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 4) to collect any information on any 
safety concerns, dec rease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the investigator determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144315]'s participation in 
the study .  
S. In addition to the time points indicated on the study schedule,  OCT -A should be perf ormed at the time of any suspected new active CNV . If new active CNV  is confirmed  in the 
study eye , OCT -A should be repeated every 2 months  for the study eye.  
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomization visit, then the 
administration  of pegcetacoplan  or sham should be done within [ADDRESS_1144316] 202 0 
APPENDIX E: NATIONAL EYE INSTITUTE VISUAL FUNCTIONING 
QUESTIONNAIRE 25- ITEM VERSION  
  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144317] 202 0 
APPENDIX F: FUNCTIONAL READING  INDEPENDENCE INDEX (FRI)  
Kimel M, Yu R, Leidy N. The Functional Reading Independence Index (FRI Index) - User Manual 
(Version 1.2). Evidera . [ADDRESS_1144318] 202 0 
APPENDIX G: MINNESOTA LOW-VISION READING TEST (MNREAD)  
AND RADNER READING CARDS      
The manual of procedures should be referenced for a detailed table of countries and languages to 
determine which test will be administered . Equipment and testing procedures will also be 
described in detail in the manua l of procedures for both tests.  
Minnesota Low-Vision Reading Test: 
The Minnesota Low- Vision  Reading Test acuity cards are continuous- text reading -acuity cards 
used for measuri ng the reading acuity and speed of normal and low-vision patients. These charts 
were developed at the Minnes ota Laboratory for Low-Vision Research, University of Minnesota, 
Minneapolis, Minnesota, [LOCATION_003].  
The MNREAD Acuity Charts will be used to measure:  
• Critical Print Size: the smallest print that the patient can read with maximum speed  
• Maximum Reading Speed: the patient’s reading speed when reading is not limited by 
[CONTACT_825173]:  
The Radner Reading Cards consist of sentence optotypes, which are optimized reading test items, standardized by [CONTACT_758150] . These cards  allow for accurate and 
comparable measurements of reading acuity  and reading speed and measurement of critical print 
size. 
 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144319] 202 0 
APPENDIX H: GRADING SCALE FOR  ASSESSMENT OF ANTERIOR 
CHAMBER FLARE OR CELLS  
AQUEOUS REACTION—FLARE  
Grade  Description  
0 No protein is visible in the anterior chamber when viewed by [CONTACT_825174]; a small, bright, focal slit-beam of white light; and high 
magnification.  
Trace  Trace amount of protein detectable in the anterior chamber . This prote in is visible only 
with careful scrutiny by [CONTACT_825175]; a small, 
bright, focal slit -beam of white light; and high magnification.  
1+ Mild amount of protein detectable in the anterior chamber. This protein is immediately apparent to an experienced observer using slit lamp  biomicro scopy and high magnification, 
but such protein is detected only with careful observation with the naked eye and a small, bright, focal slit -beam of white light. Note presence of any fib rin. 
2-3+ Moderate amount of protein detectable in the anterior chamber. These grades are similar to 1+ but the opacity would be readily visible to the naked eye of an observer using any source of a focused beam of white light. This is a continuum of moderate opacification, with 2+ being less apparent than 3+. Note presence of any fibrin.  
4+ A large (severe) amount of protein is detectable in the anterior chamber . Similar to 3+, but 
the density of the protein approaches that of the lens. Additionally, frank fibrin deposition is frequently seen in acute circumstances . It need s to be noted that because fibrin may 
persist for a period of time after partial or complete restoration of the blood -aqueous 
barrier, it is possible to have resorbing fibrin present with lower numeric assignations for 
flare (eg, 1+ flare with fibrin).  
 
AQUEOUS REACTION—CELLS  
Grade  Description  
0 No cells are seen in any optical section when a large slitlamp  beam is swept across the 
anterior chamber.  
Trace  Rare (1 -3) cells are observed when the slit lamp  beam is swept across the anterior chamber . 
When the instrument is held stationary, not every optical section contains circulating cells.  
1+ 3-10 cells/optical section are seen when the slit lamp  beam is swept across the anterior 
chamber . When the instrument is held stationary, every optical section contains circulating 
cells. Note stage of hypopyon, if applicable.  
2+ 10-25 cells are seen when the slit lamp  beam is swept across the anterior chamber. When 
the instrument is held stationary, every optical section contains circulating cells . Note 
stage of hypopyon, if applicable.  
3+ 25-50 cells are seen when the slit lamp  beam is swept across the anterior chamber. When 
the instrument is held stationary, every optical section contains circulating cells . Keratic 
precipi[INVESTIGATOR_66306] . Note stage of 
hypopyon, if applicab le. 
4+ More than [ADDRESS_1144320] 1+ circulating cells in the anterior chamber with a resolv ing 
hypopyon. 
 
  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144321] 202 0 
APPENDIX I: GRADING SCALE FOR ASSESSMENT  OF VITREOUS 
CELLS  
Grade  Description  Cells in Retro -Illuminated Field  
0 Clear  0 
Trace  Few opacities  1-20 
1 Scattered opacities  21-50 
2 Moderate opacities  51-100 
3 Many opacities  101-250 
4 Dense opacities  ≥ [ADDRESS_1144322] 202 0 
Section revi
sed to further define approved methods of contraception 
include:  
• Combined (estrogen- and progestogen- containing) hormonal 
contraception associated with inhibition of ovulation:  
o Oral 
o Intravaginal  
o Transdermal  
• Progestogen- only hormonal contraception associated with 
inhibition of ovulation:  
o Oral 
o Injectable  
o Implantable  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Vasectomized partner (provided that partner is the sole sexual 
partner of the WOCBP trial participant and that the 
vasectomized partner has received medical assessment of the 
surgical success)  
• Sexual abstinence (defined as refraining from heterosexual 
intercourse during the entire period of risk associated  with the 
study treatments) . Sexual abstinence is only accepted when it is 
the preferred and usual lifestyle of the subject.  
Approved methods of contraception include: oral contraceptives, 
intrauterine device, medically acceptable barrier methods 
(diaphragm or condom), implantable or injectable contraceptives 
(like DepoProvera) or removable birth control device (like 
NuvaRing or Ortho Evra patches); and/or surgical sterilization (at 
least 6 months before dosing) . Subjects practicing abstinence and 
coitus in terruptus (pull out method) must agree to use an approved 
method of contraception during the study and [ADDRESS_1144323] 
dose of study drug.  Section  6.4  Approved Methods of 
Contraception  
The following section was added:  
 
A subject may withdraw from the study at  any time for any reason 
without prejudice to his/her future medical care by [CONTACT_30363] . The investigator or sponsor may withdraw the subject at any 
time (e.g., in the interest of subject safety) . The inve stigator is 
encouraged to discuss withdrawal of a subject from treatment with the 
investigational product with the m edical monitor when possible.  
Subjects who discontinue treatment with the investigational product can 
continue participation in the study and should be encouraged  to return to 
the clinical site for as many follow -up visits as they can. In the event that 
a subject terminates early from the study, all early termination 
procedures should be performed even if they are outside the allowed 
study window .  
The reason for term ination, date of stoppi[INVESTIGATOR_825144], all follow -up information and the total amount of 
investigational product administered must be recorded in the case report 
form (CRF) and source documents.  Section  6.[ADDRESS_1144324] 202 0 
 
 
The requirement to notify the sponsor prior to unmasking was removed:  
 
In the event of a medical emergency where the knowledge of subject 
treatment by [CONTACT_758153] (e.g., the subject or his/her physician) i s 
required, an individual Investigator (or designee) will have the ability to unmask the treatment assignment for a specific subject and share that 
information with the appropriate parties . The Investigator (or designee) 
must endeavor to notify the Sponsor  prior to unmasking a subject .  Section  7.2.1  Unmasking  
Section was revised to allow study treatment administration to occur on a 
day separate from the assessment visit:  
 
Section was revised to allow study treatment administration to occur on a 
day separate from the assessment visit:  
 
Only qualified study staff and those delegated the responsibility of study 
drug administration on the Delegation of Authority log should perform 
this procedure . All staff should be appropriately trained on all procedures 
prior to performing the procedures . Sites should follow the Visit 
Schedule for order of procedures and assessments .  
Administration of study treatment (APL -2 or Sham) can be done on a 
separate day from the assessment visit if both days fall within the visit 
window . If this occurs on the randomization visit, then the administration 
of APL -[ADDRESS_1144325] should be scheduled on time for the 
next dosing visit.  Section  7.3.2  Treatment 
Administration  
The description of sham injection was modified as there is no 
requirement for sham to be sterile:  
 
Sham will be provided as sterile  empty stoppered glass vials and should 
be stored according to the label .   
 Section  [IP_ADDRESS] Ide ntity of the 
Investigational Product  
The procedure for sham injection was further described:  
 
The procedure for sham injection will be the same as that used for IVT 
injection until the actual injection but no actual injection will occur. The 
injecting phy sician will only touch the study eye with the blunt end of 
the syringe . No needle or medication will be injected inside the eye . Section  7.[ADDRESS_1144326] was defined:  
 
The end of the trial for each subject is defined as when the subject either 
completes their Mont h [ADDRESS_1144327] completes their exit visit at Month 30.  
 
Through the section it has also been noted that endothelial cell count 
assessment is for “select sites only”. This was previously no ted in the 
schedule of events but not consistently in the body of the protocol . In 
addition FAF and NAR are no longer “study eye only”.  
 Section  8  Study Procedures  
The fo llowing assessments were removed as they will no longer be 
conducted at the screenin g Visit 1: 
• Low luminance BCVA  
• Endothelial cell count  
• OCT A 
The following text was moved to Section  8.1.2 as training for home -
based digital applications will now be conducted at Visit 2: 
Prior to dilating the eyes, subjects at select sites will be trained on how to 
use the home based digital applications for visual function and reading 
speed if the subje ct decides to participate in this portion . This training 
must occur after completion of all functional tests (NL BCVA, LL
BCVA).  Section  8.1.1  Visit  1 All Subjects  
It was clarified that:  
All assessments should be performed on the same day. All study visits 
should be scheduled and projected based on the Day  1 visit.  
 
The following text was added as home -based digital application training 
will now occur at Vi sit 2: 
Subjects at select sites will be trained on how to use the home -based 
digital a pplications for visual function and reading speed if the subject 
decides to participate in this portion . This training must occur after 
completion of all functional tests  (NL-BCVA, LL -BCVA).  
 The following assessments were added:  
• Endothelial cell count  
• OCT -A (select sites)  
 
The following text was removed as subject discontinuation is now 
covered in Section  6.5. 
In the event that a subject is early terminated from the study , all early 
termination procedures should be performed even if they are outsi de the 
allowed study window .  
If the subject would like to discontinue dosing but is amenable to Section  8.1.2 Randomization/Init ial 
Treatment —Day —Within [ADDRESS_1144328] complete as many follow up visits as possible.  
 
It has been noted in the text which assessments will be conducted at 
Month 27 and Month 30.  Section  8.1.4 Follow -up Phase  
Instructi ons were revised to include the following:  
 
All AEs encountered during the study will be monitored and reported in 
detail in the source documents and documented on the eCRF, from 
signing of the ICF until the Exit Visit. AEs should be recorded by 
[CONTACT_825176] . AEs, especially those for which the relationship to 
test drug  study treatment are considered by [CONTACT_758154], should be followed up until they have 
returned to the baseline status or stabilized . If a clear explanat ion is 
established, it should be recorded on the eCRF.  Section  11.2   Recording Adverse 
Events  
Instructions modified as follows:  
If any AEs are serious, special procedures will be followed. All SAEs 
will be reported to the Safety Monitor by [CONTACT_825177], whether 
or not the serious events are deemed drug related . SAE reporting contact 
[CONTACT_758156]. All SAEs must be reported to the applicable ethics 
committee by [CONTACT_39600].  
 
Special procedures will be followed for reporting SAEs . All SAEs 
will be reported to the Safety Monitor by [CONTACT_825178]/email (if eCRF is not available)  within [ADDRESS_1144329] complete the appropriate 
paper SAE form and fax/email to the number listed o n the SAE form, 
also within [ADDRESS_1144330] be reported to the 
applicable ethics committee by [CONTACT_758158].  Section  11.5 Serious Adverse Events  
The following text was added:  
A suspected adverse reaction means any AE for which there is a 
reasonable possibility that the drug caused the AE . Reasonable 
possibility means there is evidence (such as a temporal relationship) to 
suggest a causal relationship between the drug and the AE.  Section  11.6 Unexp ected Adverse 
Events or Unexpected Suspected 
Adverse Reactions  
The analysis description was modified as follows as this will be 
conducted at all sites . This is an error correction.  
• Change from baseline at each planned assessment in the total area of 
GA les ion(s) in the study eye (in mm2) as assessed by [CONTACT_737262] (in select 
sites)   Section  12.7.[ADDRESS_1144331] 202 0 
Section  12.10 was added to describe how visit windows will be used  in 
the assessment of the primary endpoint:  
 
Analysis visits will be derive d with windows for the monthly visits to 
assess the primary endpoint . Baseline is defined as the date of 
randomization . If [ADDRESS_1144332] visit to the target day will be used as that analysis visit; if 2 visits 
are equidistant from the scheduled analysis visit day, the later analysis 
visit will be used.  Section  12.10 Visit Windows  
All study schedules were modified to align with the changes noted 
above, including removal of PK and complement profile study 
assessments.  Appendix A, B, C, and D:  Visit 
Schedules  
 
  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144333] 202 0 
associated with inhibition of ovulation,  oral contraceptives,  intrauterine 
device, intrauterine hormon ereleasing system; and/or bilateral tubal 
occlusion (at least 6 months before dosing)  medically acceptable barrier 
methods (diaphragm or condom), implantable or injectable 
contraceptives (like DepoProvera) or removable birth control  device (like 
NuvaRing or Ortho Evra patches); and/or surgical sterilization (at least 6 
months before dosing) . Subjects practicing abstinence and coitus 
interruptus (pull out method) must agree to use an approved method of 
contraception during the study a nd [ADDRESS_1144334] dose of 
study drug.  
Masking language was modified to indicate that the PI [INVESTIGATOR_758094]’ treatment assignments, while the treating physician and any associated support staff involved in IP administration 
will be unmasked.  Section  7.2 Masking and 
Minimization of Bias  
Guidance on the treatment of new exudation related to  active choroidal 
neovascularization in the study eye and/or fellow eye was modified t o 
clarify that the reading center will provide a report to indicate whether or 
not there is evidence of active, exudative AMD, and the Investigator will 
then determine if  anti-VEGF treatment should be initiated . The 
Investigator should wait for the reading center report before making a 
decision regarding treatment, except in cases where there is clear evidence of disease activity that may have a detrimental visual impact i f 
not treated immediately.  
 It was also clarified that either ranibizumab or afliberce pt should be 
selected as the anti -VEGF therapy, and that the unmasked physician 
should administer anti -VEGF treatment if the treatment is administered 
on the same day as APL -2.  
 
It was also noted that any treatments of therapi[INVESTIGATOR_825145] 5 years of screening should be recorded as a 
concomitant medication . Section  7.5.1 Treatment of New 
Exudation Related to Active 
Choroidal Neovascularization in the 
Study Eye and/or Fellow Eye  
Visit Schedules A -D 
The following instruction regar ding electronic devices was added:  
The subject will be instructed to bring back the electronic device for the 
visits specified in the schedule of events.  Section  [IP_ADDRESS] Months 1 -12 
Month 6 and Month 12 were added as times of in -clinic assessment.  
It was noted that subjects will take electronic devices home at Day  1 
instead of at Screening.  Section  9.12 Home -Based 
Functional Digital Applications (in select sites/countries)  
Visit Schedules A -D. 
Clarified that:  
In the event that a subject is suspected to ha ve new active CNV in the 
study eye and/or the fellow eye, an SD -OCT and FA using the protocol 
specified procedures should be performed and sent to the Reading Center  
to confirm the diagnosis . In addition, in selected sites, OCT -A should 
also be captured according to the study imaging protocol and sent to the 
Reading Center .  Section  9.[ADDRESS_1144335] be 
taken approximately every 3 0 minutes thereafter until IOP ≤ [ADDRESS_1144336] -Injection 
Assessment; Visit Schedule 
Footnote “O” (all Visit Schedules ) 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144337] will be performed for  screening . 
 
Footnotes “M” (All Visit Schedules) was modified to indicate that 
“Beginning at Day  1 Screening, subjects will complete the functional 
assessments weekly at home.”  Visit Schedules A and C  
 
Week  24 blood draw for clinical repository was added (error correc tion).  
 Visit Schedule C  
The full version of the NEI VFQ -[ADDRESS_1144338] 202 0 
“Endothelial cell count” was removed as an assessment that will be 
provided to the reading center for objective assessment of subject 
eligibility . 
 
“Optical Coherence Tomography Angiography (OCT -A, selected sites 
only)” was added as an assessment that will be provided to the reading 
center for objective assessment of subject eligibility .  Section  7.1 Alloca tion to Treatment  
Section  8.1. Study Visit Schedule  
Section  8.1.2 Randomization/Initial 
Treatment  
“Country” and “microperimetry eligibility (yes; no) ” were removed as a 
stratification factor.  Section  7.1 Allocation to Treatment  
 
References to “DSMB” upda ted to “DMC”.  Section  7.2.[ADDRESS_1144339] -2 for injection was removed from the 
paragraph describing sham.  Section  [IP_ADDRESS] Identity of the 
Investigational Product  
Text was updated to indicate t hat:  
 
The suspected onset or presence of new active choroidal 
neovascularization (CNV) secondary to AMD in the study eye and/or 
fellow eye  must be documented in the source document and CRF .  Section  7.5.1 Treatment of New 
Active Choroidal 
Neovascularizati on in the Study Eye 
and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Optical Coherence Tomography Angiography (OCT -A) was added as a 
monitoring assessment for  select sites  to confirm the diagnosis of new  
active CNV . Section  7.5.1 Treatment of New 
Active Chor oidal 
Neovascularization in the Study Eye and/or Fellow Eye  
Section  9.15 Ocular Imaging  
Text corrected as follows:  
 
The treatment method (pars plana vitrectomy vs  intravitreal injection of 
antibiotics  vitreous tap ) and choice of antimicrobial agents are a lso at the 
discretion of the physician and should follow current standard practice 
patterns .  Section  7.5.3 Endophtha lmitis 
Treatment  
Content in these sections was combined.  Section  7.5.1 Treatment of New 
Active Choroidal 
Neovascularization in the Study E ye 
and/or Fellow Eye  
 
Section  7.5.2 Treatment of 
Neovascular AMD in the Fellow Eye 
References to “biobanking” have been replaced by [CONTACT_758159] 
“genetic biorepository” and the “clinical repository” .  Section  8. STUDY DESIGN  
Section  9.7 Genotypi[INVESTIGATOR_825146]  9.17 Blood Volume for 
Study Assessments  
Protocol updated to specify that microperimetry should be conducted on 
both eyes.  Section  8 STUDY DESIGN  
Noted that blood draws will be conducted for genotypi[INVESTIGATOR_007].  Section  [IP_ADDRESS] Months [ADDRESS_1144340] 202 0 
should be masked to the treatment assignment  only; the protocol 
previously stated that staff should also be blinded to the study eye . Acuity and Low Luminance Best -
corrected Visual Acuity  
Blood volume for genetic biorepository was updated.  Section  9.17 Blood Volum e for 
Study Assessments  
The following samples were removed:  
• All residual serum and whole blood samples 
collected during the course of the study for PK 
analysis, genotypi[INVESTIGATOR_825147] 2 antibody 
formation  
• Residual serum PK sample  
• Residual serum Anti Therapeut ic Antibodies 
(ATA) sample  
 
It was noted that the 15 mL whole blood sample will be collected at 
Month 2 , baseline , Month 12 and Month 24 of the study  Section  9.18.2 Sample Collection  
It was clarified that the DMC will meet at the beginning of the study an d 
every 6 months thereafter.  Section  10.1 Data Monitoring 
Committee  
Reference to “possibly related” AEs was removed as there is no 
“possibly related” AE categorization for this study.  
 
Resolution outcome possibilities were updated to accurately align with the SAE report forms that will be used for this study.  Section  11.2 Recording Adverse 
Events  
 Section  11.4.1 Relationship of 
Events to Study Treatment  
Clarified that:  
All SAEs will be reported to the Safety Monitor by [CONTACT_825179], whether or not the serious events are deemed drug -related.  Section  11.[ADDRESS_1144341] protocol 
specifications for data management and statistical considerations more clearly, accurately, and thoroughly.  Section  12. DATA MANAGEMENT 
AND STATISTICAL CONSIDERATIONS  
Footnote was updated to indicate that : All assessments should be 
performed on the same day , with the exception of screening . 
 The blood draw for the clinical repository was removed at baseline, 
Month 1, Month 8, Month 18, and Month 27.  
 
OCT -A was added at screening, Month 6, Month 12, Month 18, and 
Month [ADDRESS_1144342] sites . Footnote “R” was added to note that i n 
addition to the time points indicated on the study schedule, OCT -A 
should be performed at the time of any suspected new active CNV . If 
new active CNV is confirmed in the study eye, OCT -A should be 
repeated every 2 months for the study eye . All Study Schedules (Appendice s: 
A, B, C, and D)  
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144343] 202 0 
APPENDIX K: PROTOCOL CHANGES TO BE FOLLOWED DURING 
COVID- [ADDRESS_1144344] been 
implemented . These changes should be followed only during COVID-19 restrictions and include 
extended IP administration windows, changes to masking rules, rescreening instructions, and a revised schedule of assessments .  
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). 
EXTENDED IP ADMINISTRATION WINDOWS  
In order to allow more flexibility to sites and subjects, and to potentially mitigate missed IP admin istration, an extended IP administration window can be followed. Th e extended window 
can ONLY be used in situations related to COVID- 19 restrictions and after medical monitor 
approval. Footnote “T” of each COVID -19 assessment table below reflects these ext ended IP 
options. 
Per protocol, the study window is as followed: 
• Monthly treatment group: +/ –8 days for the entire study duration 
• EOM treatment  group: +/ –[ADDRESS_1144345] study year and +/–16 days for the 
second study year 
During COVID- 19 restrictions, the IP administration  window can be extended to the following: 
• Monthly treatment group: –8 days to +[ADDRESS_1144346] 14 days.  
• EOM treatment group: –8 days to +[ADDRESS_1144347] study year and –16 days to +30 days for the second study year 
MASKING RULES  
Due to current COVID- 19 restrictions, clinical sites might encounter difficulties maintaining 
appropriate clinic staffing to satisfy the approved masking rules for the APL2-304 ( Oaks ) study. 
Based on thi s, and in an attempt to minimize the amount of missed data and IP administrations, 
Apellis is implementing a  temporary  adjustment to the study masking rules.  
This temporary change must be approved by [CONTACT_825180] d must be documented via a temporary and modified Delegation of Authority 
Log. Each masked assessment performed by [CONTACT_758162] (even with Apellis 
approval and following the below guidelines) should be documented.  
The principal investigator (PI) is responsible for the overall safety oversight of the study site data 
and s/he will not be allowed to switch into an unmasked role. Every masked individual that 
performs IP administration and/or post injection  assessment (all unmasked assessment ) as a 
temporary measure, will permanently  be considered an  unmasked individual and will not be 
able to perform masked  assessments once these exemptions are lifted . 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144348] was deemed a screen failure for not being able to meet the original screening window 
(Day –28 to Day –1 [+/–2 days]) due to COVID -19 related restrictions, a rescreening visit is 
allowed and should be followed according to the 2 scenarios below .  
Subjects Who  Completed Screening and Were Considered Eligible by [CONTACT_825181] 30 March  2020 and completed  all screening assessments (as 
described in the Schedule of Assessments Appendix A [every month treatment group] and 
Appendix C  [every -other-month [EOM] treatment gr oup]) and considered eligible by [CONTACT_825182] [ADDRESS_1144349] ID number and undergo an abbreviated screening, prior to randomization, 
that includes the following assessments:   
• Informed consent/Assign new screening number  
• NL-BCVA  assessment   
• Slitlamp  examination   
• Dilated indirect ophthalmoscopy  
• IOP measurement   
• SD-OCT*    
• Concomitant medication/concomitant ocular procedures collection   
• AE collection   
*SD-OCT images collected at this visit will not be used by [CONTACT_825183].  
If the investigator deems it necessary, additional assessments can be performed  if there is a 
concern that the subject might now meet an exclusion criterion that was not the case during the original screening (eg, fundus fluorescein angiography to exclude the presence of CNV). 
 
Subjec ts With Incomplete Screening Assessment   
Subjects that signed the informed consent but were not able to complete all screening assessments due to COVID-19- related restrictions  are not eligible for the abbreviated screening. 
These subjects  can be rescreened  but must follow the standard screening schedule of 
assessment  (as described in  the Schedule of Assessments Appendix A  [every month treatment 
group] and Appendix C  [EOM  treatment group]). These subjects will also receive a new 
screening ID number.  
MINIMUM SCHEDULE OF ASSESSMENT  
Schedule of Assessments   
Where feasible,  sites could continue to follow the full schedule of assessments (based on their 
treatment group assignment). The  minimum assessment tables,  only to be followed during this 
 
 
Apellis Pharmaceuticals, Inc
Page [ADDRESS_1144350] 202 0 
COVID- 19 effort  and if determined necessary to use based on the investigator’s clinical 
judgment, are provided below to reduce the time required for each study visit. Subjects  in the 
EOM treatment group do not need to be seen for the non- IP administration visits . Assessments 
not performed (even those that have been removed in the minimum assessment table) should be 
documented.  
Subjects that are not able to come into the clinic for a study visit due to COVID-19- related 
restrictions, including visits for the EOM group that do not include IP administration, should 
be contact[CONTACT_825184] (including SAEs) and 
concomitant medications . All SAEs are still required to be reported to Apellis within [ADDRESS_1144351] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be p erformed for the study eye only on days where 'SE' is specified 
and for both eyes at all other visits as specified in the above schedule and will be s ent to the reading center for evaluation (consult the reading center manual for specifics on 
image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be obtained at a 
specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD -OCT, FFA and OCT -A (select sites) images 
must be collected and sent to the r eading center for analysis .  
P. Posti njection assessments should be performed within 5 minutes after dosing by [CONTACT_758147] a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross v ision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be pe rformed . IOP should be  ≤[ADDRESS_1144352] the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is  
>[ADDRESS_1144353] and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab or aflibercept injection during the same visit as the study treatment ( pegcetacoplan  or sham ), the treatment with ranibizumab or 
aflibercept must be performed first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 3) to collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as  soon as possible .  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) us ed by [CONTACT_25701] [ADDRESS_1144354]'s participation in 
the study .  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be don e on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occ urs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144355] be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + [ADDRESS_1144356] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for 
specifics on image capture, processing, and transmis sion) . Images should be captured  prior to dosing on dosing days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is sus pected, SD -OCT, FFA, and OCT -A 
(selected sites) images should be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_825185] a gross assessment of vision  (finger-
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision test, the tonometry 
should be performed . IOP should b e ≤[ADDRESS_1144357] the site . If necessary, anti glaucomatous  medication can be given to lower the IOP . If IOP is 
>[ADDRESS_1144358] and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment ( pegcetacoplan or sham ), the treatment with ranibizumab  or 
aflibercept  must be  performe d first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 3) t o collect any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as pos sible .  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144359]'s participation in 
the study .  
S. In addition to the time points indicated on the study schedule , OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on se parate days fr om the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if both days fall within the visit window . If this occurs on the randomizat ion visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144360] be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + [ADDRESS_1144361] images, near infrared reflectance, fluorescein angiograms, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes at all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center manual for 
specifics on image capture, processing, and transmission) . Images should be captured prior to dosing on dosing days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at  the next scheduled visit . If new active CNV is suspected, SD -OCT, FFA, and OCT -A 
(selected sites) images should be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after dosing by [CONTACT_758147] a gross assessment of vision (finger -
counting, hand motion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gross vision te st, the tonometry 
should be performed . IOP should be  ≤[ADDRESS_1144362] the site. If necessary, antiglaucomatous medication can be given to lower the IOP. If IOP i s 
>[ADDRESS_1144363] and IOP is ≤3 0 mm Hg. Note: if 
the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment ( pegcetacoplan or sham), the treatment with ranibizumab  or 
aflibercept  must be performed first . The pre - and  post- anti-VEGF IOP values must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days after each study treatment visit (through Month 4) to collect  any information on any 
safety concerns, decrease in vision, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the physician determines that there are any safety concerns, 
a follow -up visit should be scheduled as soon as poss ible.  
R. Record concomitant medications ( ie, prescription and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144364]'s participation in 
the study .  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of any suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on separate  days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visi t if both days fall within the visit window . If this occurs on the ra ndomization visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144365] be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 8 days to + [ADDRESS_1144366] images, near infrared reflectance, fluorescein angiogr ams, and fundus photographs will be performed for the study eye only on days where 'SE' is 
specified   and for both eyes a t all other visits as specified in the above schedule and will be sent to the reading center for evaluation (consult the reading center  manual for 
specifics on image capture, processing, and transmission) . Images should be captured prior to dosing on dosin g days . If a subject misses a study visit or images cannot be 
obtained at a specific visit, study staff should make every effort to obtain images at the next scheduled visit . If new active CNV is suspected, SD-OCT,  FFA,  and OCT -A 
(selected sites)  images sh ould be collected and sent to the reading center for analysis .  
P. Postinjection assessments should be performed within 5 minutes after  dosing by [CONTACT_758147] a gross assessment of vision (finger -
counting, hand m otion, then light perception when applicable) . If subject passes gross vision test, the subject may leave the site. If subject fails gr oss vision test, 
the tonometry  should be performed. IOP should be ≤[ADDRESS_1144367] the site. If necessary, antiglaucomatous medication can be given to lower the 
IOP. If IOP is > [ADDRESS_1144368] and IOP is 
≤30 mm Hg. Note: if the study eye is treated with a ranibizumab  or aflibercept  injection during the same visit as the study treatment (pegcetacoplan  or sham), the treatment with 
ranibizumab  or aflibercept  must be performed first . The pre - and post - anti-VEGF IOP valu es must be measured and recorded on the eCRF .  
Q. Starting at Day  1, study subjects will be contact[CONTACT_758148] 4 ± 2 days af ter each study treatment visit (through Month  4) to collect any information on any 
safety concerns, decrease in vi sion, eye pain, unusual ocular events , or any new ocular symptoms in the study eye . If the  investigator  determines that there are any safety 
concerns, a follow -up visit should be scheduled as soon as possible .  
R. Record concomitant medications ( ie, prescr iption and over -the-counter medications) used by [CONTACT_25701] [ADDRESS_1144369]'s participation in 
the stu dy.  
S. In addition to the time points indicated on the study schedule, OCT -A should be performed at the time of a ny suspected new active CNV . If new active CNV is confirmed in the 
study eye, OCT -A should be repeated every 2 months for the study eye .  
T. Administration of pegcetacoplan  or sham  can be done on separate days from the assessment visit if both days fall within the visit window . Administration of study treatment 
(pegcetacoplan  or sham) can be done on a separate day from the assessment visit if bo th days fall within the visit window . If this occurs on the randomization visit, then the 
administration of pegcetacoplan  or sham should be done within [ADDRESS_1144370] be done on the day of study treatment administration is pre injection  IOP. During the COVID -19 pandemic, the 
following flexibility is allowed for IP administration: – 16 days to + 30 days after medical monitor approval . 
 
 
 
Apellis Pharmaceuticals, Inc
Page 164 of 164
Confidential